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ABSTRACT 
 
Christopher Brooke 
Evaluation of the Protective Roles of Complement Activation and T cells During 
Venezuelan Equine Encephalitis Virus Infection 
(Under the direction of Robert E. Johnston) 
 
Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne alphavirus that 
can cause a potentially lethal encephalomyelitis in humans and equids.  There is 
currently no licensed vaccine available for use in humans.  Efforts to understand the 
host requirements for successfully controlling VEEV infection have been limited by 
the extreme lethality of the virus in small animal models.  Here we describe the use 
of the V3533 mutant of VEEV as a model for successful control of VEEV infection.  
Following peripheral inoculation of a mouse, V3533 behaves similarly to lethal 
strains of VEEV.  Rapid replication of V3533 in secondary lymphoid organs results in 
the development of a serum viremia, followed by viral invasion of the central nervous 
system (CNS).  The infection is short-lived, however, as the development of an 
adaptive immune response results in clearance of infectious virus from all tissues by 
day 8 post-infection.  Using this model we identified previously unappreciated roles 
for complement activation and T cells in promoting recovery from VEEV infection.  
  iii 
Complement activation within the first 24 hours of infection enhanced serum 
clearance and delayed viral invasion of the CNS, preventing the development of 
overt encephalomyelitis.   This effect was independent of anti-VEEV antibody 
induction or inflammatory cell recruitment.  In addition, we showed that T cells, 
particularly CD4+ T cells, were capable of controlling V3533 infection in the CNS and 
facilitating recovery from severe encephalomyelitis in the absence of antibody.  
Together, these results provide a starting point for future efforts to identify the 
requirements of a protective host response to VEEV infection. 
  iv 
 
 
 
ACKNOWLEDGMENTS 
 
 
This work would not have been possible without the help and guidance of numerous 
people.  I would like to thank my advisor, Robert Johnston, for his support of my 
research.  Additionally, I would like to thank the members of my committee, Ralph 
Baric, Jeff Frelinger, Mark Heise, and Glenn Matsushima, for input and advice on a 
number of subjects.  The members of the Carolina Vaccine Institute, in particular 
Nancy Davis, Laura White, Tem Morrison, Alan Whitmore, and Alex Schaefer, 
provided a great deal of helpful advice as well as experimental assistance in some 
cases.  Finally, Jeff Frelinger, Nancy Davis, Alex Schaefer, and Laura White 
provided critical input on the text of the third chapter of this dissertation.  
  v 
 
 
 
TABLE OF CONTENTS 
 
List of tables...........................................................................................................viii 
List of figures..........................................................................................................ix 
List of commonly used abbreviations...................................................................x 
1. Introduction........................................................................................................1 
Venezuelan equine encephalitis virus (VEEV) biology...................................2 
Genomic organization................................................................................2 
Replication strategy...................................................................................3 
  Entry and uncoating.............................................................................4 
  Translation and replication...................................................................6 
  Packaging and egress……………………….........................................9 
Host cell effects.........................................................................................11 
  Transcription/Translation shutoff.........................................................11 
  Inhibition of IFN signaling....................................................................12 
  Apoptosis.............................................................................................13 
VEEV mouse model..................................................................................14 
Immunity to VEEV.....................................................................................18 
Anti-VEEV vaccines..................................................................................22 
Use of VEEV reverse genetics..................................................................23 
  vi 
Complement system overview.......................................................................26 
Complement activation pathways.............................................................27 
Complement cascade...............................................................................28 
Effector mechanisms................................................................................29 
Overview of central nervous system (CNS) immunity....................................33 
Resting state.............................................................................................33 
Immune induction......................................................................................35 
Regulation of CNS immune responses.....................................................36 
Clearance of virus from neurons...............................................................38 
References.....................................................................................................41 
 
2. Early interactions with the host complement system  
determine downstream disease outcome following  
Venezuelan equine encephalitis virus infection.............................................78 
Abstract..........................................................................................................79 
Introduction.....................................................................................................80 
Materials and methods...................................................................................83 
Results...........................................................................................................87 
Discussion......................................................................................................95 
References...................................................................................................102 
 
3. T cells facilitate recovery from Venezuelan equine  
encephalitis virus-induced encephalomyelitis in the absence  
of antibody.......................................................................................................122 
Abstract........................................................................................................123 
  vii 
Introduction..................................................................................................124 
Materials and methods.................................................................................127 
Results.........................................................................................................131 
Discussion....................................................................................................144 
References...................................................................................................153 
 
4. Comparison of V3000 and V3533 cellular tropism within the 
brain..................................................................................................................175 
 
Introduction...................................................................................................176 
Materials and methods.................................................................................177 
Results and discussion.................................................................................178 
References...................................................................................................180 
 
5. Discussion and future directions...................................................................182 
Determination of the mechanisms of V3533 attenuation..............................183 
Further exploration of VEEV-complement interactions.................................186 
Further investigation of the T cell response to VEEV and  
VEEV persistence.........................................................................................190 
References...................................................................................................194 
 
  viii 
LIST OF TABLES 
 
Table 3-1:     Percentage of brain-infiltrating T cells expressing  
indicated cytokines at day 70 post-infection.....................................174 
  ix 
 LIST OF FIGURES 
 
Fig. 2.1:  Complement activation limits disease severity following  
     V3533 infection.....................................................................................111 
 
Fig. 2.2:  V3533-induced brain inflammation in C57BL/6 and C3-/-           
      mice......................................................................................................113 
 
Fig. 2.3:  V3533 tissue titers in C57BL/6 and C3-/- mice......................................114 
 
Fig. 2.4:  Disease outcome following intracranial inoculation of     
      V3533...................................................................................................116 
 
Fig. 2.5:  Anti-VEEV neutralizing activity of normal serum is partially  
     dependent on complement activation...................................................118 
 
Fig. 2.6:  Anti-VEEV antibody response is intact in C3-/- mice.............................119 
Fig. 2.7:  Inflammatory cell recruitment to early sites of V3533  
     replication is complement-independent................................................121 
 
Fig. 3.1:  V3533-induces mild, transient disease followed by clearance  
     in C57BL/6............................................................................................162 
 
Fig. 3.2:  Rag1-/- mice succumb to V3533 infection while µMT mice     
      recover..................................................................................................164 
 
Fig. 3.3:  Recovery in µMT mice is associated with control of viral  
     replication in the brain, clearance in the spinal cord.............................166 
 
Fig. 3.4:  Reduction of viral titers in the CNS coincides with influx  
     of T cells, inflammatory monocytes.......................................................168 
 
Fig. 3.5:  T cells are required for control of infection, recovery in µMT      
      mice.......................................................................................................170 
 
Fig. 3.6:  CD4+ T cells are the main producers of T cell-associated  
     IFNγ within the brains of V3533-infected µMT mice...............................172 
 
Fig. 4.1:  V3533 mutations do not alter the cellular tropism of VEEV  
     within the CNS........................................................................................181 
  x 
LIST OF COMMONLY USED ABBREVIATIONS 
 
AF – Alexa-fluor 
APC – Antigen presenting cell, or allophycocyanin 
AST – Average survival time 
BBB – Blood brain barrier 
cDNA – Complementary DNA 
CNS – Central nervous system 
DNA – Deoxyribonucleic acid 
eGFP – Enhanced GFP 
FITC – Fluorescein isothiocyanate 
GFP – Green fluorescent protein 
H&E – Haematoxylin and eosin 
HSV – Herpes simplex virus 
i.c. – Intra-cranial 
IFN - Interferon 
i.p. – Intra-peritoneal 
LCMV – Lymphocytic choriomeningitis virus 
MAb – Monoclonal antibody 
MAC – Membrane attack complex 
MHC – Major histocompatibility complex 
MHV – Mouse hepatitis virus 
nsP – Nonstructural protein 
  xi 
PE – Phycoerythrin 
PFU – Plaque forming unit 
P.I. – Post-infection 
PMA – Phorbol 12-myristate 13-acetate 
PRR – Pattern recognition receptor 
RLR – Rig-I-like receptor 
RNA – Ribonucleic acid 
s.c. – Sub-cutaneous 
SEM – Standard error of the mean 
SF – Semliki Forest virus 
SIN – Sindbis virus 
TD – Trinidad donkey (VEEV strain) 
TLR – Toll-like receptor 
TMEV – Theiler’s murine encephalomyelitic virus 
VEEV – Venezuelan equine encephalitis virus 
VRP – VEEV replicon particle
  
 
 
 
 
CHAPTER 1: 
INTRODUCTION 
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Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne RNA virus of the 
genus alphavirus that is responsible for a significant disease burden in Central and 
South America through sporadic outbreaks into human and equid populations (256).  
VEEV infection in humans causes a spectrum of disease that ranges form 
asymptomatic to mild, flu-like illness to overt encephalomyelitis, with an overall case 
mortality rate of about 0.5-1%.  In equid populations, the development of overt 
encephalomyelitis is more common, and the overall mortality rate often exceeds 
50% (252).  Much of our current understanding of VEEV pathogenesis and immunity 
comes from studies carried out in a well-characterized mouse model of infection.  
Typically, VEEV infection of mice results in the development of a lethal 
encephalomyelitis within 6-8 days of infection, however, one unique VEEV mutant 
called V3533 invades and replicates within the central nervous system (CNS) of 
mice without inducing severe morbidity or mortality.  This virus has provided an 
excellent model for understanding the viral and host factors that determine whether 
infection progresses to death or successful immune control and recovery.  
Specifically, the studies described here reveal previously unappreciated roles for T 
cells and the complement system in controlling VEEV infection and influencing 
disease outcome.  In order to provide the pertinent background, the following 
sections review the current literature concerning VEEV biology, the host complement 
system, and the regulation of immune responses within the CNS. 
 
VENEZUELAN EQUINE ENCEPHALITIS VIRUS BIOLOGY 
GENOMIC ORGANIZATION 
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Venezuelan equine encephalitis virus (VEEV), a member of the genus alphavirus, is 
encoded by a single positive-sense RNA of approximately 11,400 nucleotides that is 
capped with a 5’ terminal 7-methylguanosine as well as polyadenylated at its 3’ 
terminus (119).  The 5’ two-thirds of the viral genome encodes the four non-
structural proteins (nsp1-4) in a single open reading frame.  The 3’ third of the 
genome contains a second open reading frame that encodes a subgenomic, 26S 
RNA that yields the three major structural proteins, capsid and the E1 and E2 
glycoproteins, as well as the 6K polyprotein (232).  In between these two regions lies 
a ~38 nucleotide junction region that contains the transcriptional promoter, start site, 
and non-translated leader sequence for the 26S subgenomic mRNA encoding the 
structural polyprotein.  Four conserved sequence elements (CSE) that are important 
for replication have been identified, two near the 5’ end of the genome, one in 
between the nonstructural and structural gene cassettes, and one immediately 
upstream of the poly(A) tail (125-127).  Finally, the VEEV genome is flanked by short 
nontranslated regions (NTR) at the 5’ and 3’ termini, 44 and 121 nucleotides in 
length respectively, both of which are required for replication of the genomic RNA 
(232).     
 
REPLICATION STRATEGY  
While the molecular mechanisms underlying VEEV replication have not been 
extensively examined, a great deal of research has been performed using related 
alphaviruses, including Sindbis virus (SIN) and Semliki Forest virus (SF), and it is 
thought that findings obtained in those systems apply generally across the genus 
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Alphavirus.  Therefore, findings from various alphaviruses will be discussed below 
with the assumption that they apply to VEEV as well. 
 
ENTRY AND UNCOATING 
Alphavirus attachment and entry are mediated primarily by the viral E1 and E2 
glycoproteins. These two proteins form stable heterodimers on the surface of the 
virion particle that are further organized into trimeric spikes by E1-E1 interactions 
(198, 232).  The E2 protein, which protrudes from the virion surface, is thought to 
mediate target cell recognition via interaction with an unidentified host protein 
receptor (43, 198).  The exact mechanism by which alphaviruses transmit their 
genomic RNA into the cytoplasm remains unclear.  A series of studies have 
suggested that entry occurs through virus-cell membrane fusion in the early 
endosome.  Following E2-mediated attachment, viral particles rapidly enter the cell 
via endocytosis, demonstrated by the disappearance of viral glycoproteins from the 
cell surface following SIN infection (47).  The acidification of the early endosome to 
pH ≤ 5.5 causes the reduction of glycoprotein disulfide bridges, leading to a 
conformation change in E1 that exposes the fusion domain (1, 57, 115, 150).  With 
SF, this process has been shown to occur within five minutes of attachment (89).  
Exposure of the hydrophobic, 17-amino acid fusion domain then triggers fusion of 
viral and host lipid bilayers by an as-yet undescribed mechanism, releasing the viral 
nucleocapsid into the cytoplasm (232).  Alternatively, Brown and others have 
suggested that SIN infection can occur through a membrane fusion-independent 
mechanism (191).  They showed that, following a low pH-induced conformational 
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change in the viral glycoprotein coat, SIN could bind the cell surface and release the 
viral genomic RNA into the cytoplasm without inducing membrane fusion or 
disassembling the viral protein shell.  Other studies have demonstrated SIN infection 
in the presence of weak bases, calling into question the low pH requirement for 
alphaviral entry (23, 30).   
 
The process of nucleocapsid uncoating has also best been described in the Sindbis 
virus and Semliki Forest virus systems.  Following release into the cytoplasm, 
incoming nucleocapsids rapidly associate with the large 60S subunit of host 
ribosomes (222, 258).  Binding of viral capsid protein to the 60s subunit was shown 
to require exposed rRNA sequence, as RNase pretreatment abolished binding, 
potentially a 400 nucleotide stretch of the 28S rRNA molecule that shares 54% 
sequence homology with the SIN encapsidation sequence (222, 257).  The 
association with ribosomes has been demonstrated to be both necessary and 
sufficient for the uncoating of SF virus capsid protein from the viral RNA in vitro 
(222).  Singh and Helenius hypothesized that uncoating resulted from capsid 
molecules being stripped away from the viral RNA by higher affinity binding sites on 
the 60S subunit.  This hypothesis was supported by the findings that the uncoating 
process required no energy input, occurred in a stoichiometric rather than catalytic 
fashion, and resulted in the long-term association of un-degraded capsid with the 
60S subunit (222, 232).  One problem that has kept this hypothesis from being 
universally accepted is that it does not explain how newly synthesized capsid 
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proteins are able to stably associate with viral RNA during assembly in the continued 
presence of ribosomes. 
 
TRANSLATION AND REPLICATION 
 Much of what is known about alphavirus protein translation and RNA replication was 
described in the SIN system (232).  Once released from the nucleocapsid structure, 
the incoming viral genomic RNA acts as a messenger RNA for the translation of the 
four nonstructural proteins (230).  In the case of VEEV, as well as many other 
alphaviruses including Sindbis virus, the nonstructural proteins are translated as two 
distinct polyproteins (119, 232).  The predominant species produced is the P123 
polyprotein that eventually gives rise to nsP1, nsP2, and nsP3.  Translation of the 
P123 polyprotein is terminated by an opal codon at the nsP3-nsP4 junction.  
Readthrough of the opal codon, which is estimated to occur with a frequency of 
about 10-20% in SIN, results in the production of the second polyprotein, P1234 
(139).  Upon translation of the P1234 polyprotein, cis cleavage at the nsP3/4 
junction by the protease domain of nsP2 occurs rapidly, yielding P123 and nsP4 as 
products (132, 133).  Subsequent cleavage of P123 at the nsP1/2 and nsP2/3 
junctions to yield mature nsP1, nsP2, and nsP3 is dependent upon the viral protease 
acting in trans and thus occurs with slower kinetics than the nsP3/4 cleavage (219).   
 
The four mature nsPs are multifunctional proteins that are all required for viral 
replication (232).  The nsP1 protein contains the viral guanine-7-methyltransferase 
and guanylyltransferase activities necessary for capping genomic and 26S RNA 
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(128, 164).  In addition, nsP1 is the only alphavirus nonstructural protein that has 
been shown to directly associate with cellular membranes (194).  This association, 
which is thought to occur through the combined effects of a palmitoylated cysteine 
residue at residue 420 (position in SIN) and an amphipathic α-helix between 
residues 245 and 264 (position in SF), is probably responsible for anchoring 
replication complexes to cellular membranes (127, 130).  As mentioned earlier, the 
viral papain-like serine protease is contained within the C terminus of nsP2 (229).  At 
its N-terminus, nsP2 contains helicase, NTPase, and RNA triphosphatase activities 
that are required for viral RNA replication (67, 205, 246).  The exact function of the 
nsP3 protein in viral replication remains unclear, though mutational studies have 
made it clear that it does play a role (131).  Finally, the nsP4 protein provides the 
viral RNA-dependent RNA polymerase activity (76).   
 
Productive infection of a cell by an alphavirus requires the highly orchestrated 
production of three distinct RNA species: plus-strand genomic RNA, the 
complementary minus-strand RNA, and the plus-strand subgenomic 26S RNA.  This 
process, which takes place on the cytoplasmic side of endosomal and lysosomal 
membranes, is initiated by cleavage of the P1234 polyprotein into P123 and nsP4 by 
nsP2 (55, 132).  The resultant P123+nsP4 complex catalyzes minus-strand RNA 
synthesis beginning from the 3’ CSE of the parental genome, possibly with 
unidentified host proteins serving as co-factors (62, 79, 132, 133).  Due to the 
initially small pool of both positive-sense template RNA (ostensibly a single molecule 
at first) and nsP4 (due to inefficient readthrough of the opal codon at the nsP3/4 
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junction), minus strand RNA is not produced to great abundance during infection 
(254).  Meanwhile, as P123 and P1234 continue to be translated from the input 
genomic RNA and their local concentration increases, the reaction velocity of nsP2-
mediated trans cleavage of nsP1/2 and nsP2/3 also increases, giving rise to 
nsP1+nsP2+nsP3+nsP4 complexes (232).  The transition from a P123+nsP4 
conformation to an nsP1+nsP2+nsP3+nsP4 conformation apparently alters the 
initiation template specificity of the replicase complex, converting it irreversibly to an 
efficient producer of plus-strand, but not minus strand viral RNAs (134).  Thus, the 
alphaviral replicase complex acts as a feedback switch that allows for tight temporal 
control of both plus-strand and minus-strand RNA synthesis, regulated by the 
concentration of nsPs.    
 
Once the replicase complex has converted from minus-strand to plus-strand 
synthesis, two distinct RNA species are produced: the full-length genomic 49S RNA 
and the subgenomic 26S RNA.  The genomic and subgenomic RNAs utilize different 
promoters, located in the minus-strand 3’ NTR and the junction between the 
nonstructural and structural gene cassettes, respectively (232).  Roughly ten times 
as much subgenomic RNA is produced, compared with genomic RNA, during 
infection, though the mechanism underlying this disparity is not fully understood 
(203).  A panel of mutations in nsP2 of SIN result in less subgenomic RNA being 
produced relative to genomic RNA, suggesting that nsP2 might play some role in 
determining promoter choice during plus-strand synthesis (232).  Additionally, 
differential binding of host factors to the two promoters may also play a role (44). 
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PACKAGING AND EGRESS 
Translation of the subgenomic 26S RNA results in production of the capsid-PE2-6K-
E1 structural polyprotein.  The capsid precursor is located at the N-terminus of the 
polyprotein and is thus translated first.  Once the ribosome has cleared the junction 
between capsid and PE2, a serinelike protease domain within the C-terminus of 
capsid triggers the release of mature capsid from the polyprotein by cis-cleavage 
(75).  Upon cleavage from the polyprotein, capsid remains associated with the 
ribosome and appears to rapidly assemble into core complexes around genomic 
RNA (223, 244).  This assembly process is dependent upon capsid binding of a 
specific structural element within the genomic RNA molecule called the 
encapsidation signal (141, 248).  This process has been demonstrated to occur very 
rapidly in vitro, with nothing but purified genomic RNA and capsid protein, yielding 
nucleocapsid core-like particles with T=4 icosahedral symmetry similar to cores 
purified from mature virion particles (170).   
 
Following release of the capsid protein by self-cleavage, the resultant N-terminus of 
the remaining nascent structural polyprotein acts as a signal sequence that directs 
translocation of the PE2 sequence into the ER lumen (60).  Additional downstream 
stop-transfer and signal sequences result in the structural polyprotein being stitched 
through the ER membrane such that long stretches of PE2 and E1, as well as the N-
terminus of the 6K polyprotein, are translocated into the ER lumen as well (232).  
Immediately upon translocation into the ER lumen, the envelope proteins begin a 
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complex sequence of folding and conformational changes that is dependent upon 
host chaperones and disulfide bonding (18, 19, 41, 123, 172-174).  In parallel with 
this process, the VEEV envelope proteins contain 4 N-linked glycosylation sites, one 
on E1 and three on E2, that are glycosylated within the ER lumen (118).  In the case 
of SIN, N-linked glycosylation sites on the viral envelope proteins initially receive 
high mannose chains that are then trimmed and further processed into complex 
sugars based on their physical availability to the host glycosylation machinery (218, 
255).  The glycosylation of PE2 and E1 is thought to be essential for their proper 
folding, possibly by increasing their solubility, as inhibition of the host glycosylation 
machinery prevents transport to the cell surface (155).  At an undefined stage in the 
glycoprotein folding process, PE2 begins to oligomerize with a folding intermediate 
of E1, triggering egress from the ER into the Golgi network (144).  As the viral 
glycoproteins pass into the trans-Golgi network, host furin cleaves the N-terminus of 
PE2, yielding the mature E2 glycoprotein (38).    
 
Budding of virus particles requires direct interaction between the glycoproteins and 
the nucleocapsid core (235).  Studies using cryo-EM as well as viral genetics have 
suggested that the association of the viral glycoprotein and newly formed 
nucleocapsids is mediated by interactions between the cytoplasmic tail of E2 and a 
hydrophobic pocket located within capsid (171, 234, 235, 264).  Nucleocapsids are 
thought to diffuse freely through the cytoplasm until they encounter and bind the E2-
E1 complex at the plasma membrane, at which point the actual process of 
membrane extrusion required to produce viral particles is driven by lateral 
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interactions between the glycoproteins (249).  The interactions between the 
nucleocapsid and the glycoproteins are thought to induce a further maturation of the 
nucleocapsid, as nucleocapsids isolated from mature particles sediment more 
rapidly and are more sensitive to RNase treatment, compared with nucleocapsids 
isolated fom infected cells (29).  The 6K protein, of which about five to ten molecules 
are incorporated into virions, also plays some undefined role in the budding process, 
as deletion of 6K or substitution of a heterologous 6K from another alphavirus results 
in budding defects with SF or SIN, respectively (140, 261).      
 
HOST CELL EFFECTS 
TRANSCRIPTION/TRANSLATION SHUTOFF 
One of the most studied effects of alphavirus infection is the virus-induced shutoff of 
host protein synthesis that can occur as early as three hours after infection (232).  
This process, which does not affect the production of viral protein, is primarily 
considered as a means to limit the induction of a type I interferon response by the 
infected cell (69).  Viral mutants that lack the ability to induce shutoff of host protein 
synthesis are less cytopathic, and are often capable of establishing a persistent 
infection in vitro (54).  During SIN infection, shutoff of host protein synthesis results 
from viral inhibition of host transcription and translation by discrete mechanisms 
(69).  Mechanisms of host protein synthesis shutoff differ between Old World and 
New World alphaviruses, so findings obtained with SIN or SF may not apply to 
VEEV (59).  Most of the work on VEEV-mediated host protein synthesis shutoff has 
focused on inhibition of host transcription by the capsid protein.  Residues 33-68 of 
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the VEEV capsid protein have been demonstrated to be sufficient to induce 
transcriptional shutoff, and full-length virus lacking this sequence was shown to be 
non-cytopathic, suggesting that it was incapable of mediating shutoff (58).  Both the 
full-length VEEV capsid protein, as well as the 33-68 domain by itself, associate with 
nuclear pore complexes and inhibit importin-mediated nuclear import, though no 
direct connection between this function and shutoff of host transcription has been 
demonstrated (6).  Finally, full-length VEEV virus with mutations in the 33-68 domain 
of capsid were shown to be less virulent in neonatal mice than wild-type VEEV (58).  
 
INHIBITION OF IFN SIGNALING 
Like many viruses, VEEV is sensitive to the effects of type I interferon (IFN) 
signaling (102, 260). The sensitivity of VEEV to type II IFN has not been reported, 
however SIN is quite sensitive to type II IFN treatment (12, 15, 16).  While the 
inhibition of host protein synthesis can serve as a potent means of preventing IFN 
induction in response to infection, Simmons et al. have described a separate, 
shutoff-independent mechanism by which VEEV is able to antagonize the host IFN 
response (221).  Expression of the viral nonstructural genes by non-propagating 
VEEV replicon particles (VRP) prevented the induction of IFN-stimulated gene (ISG) 
expression in response to exogenous IFN-αβ and IFN-γ by preventing the activation 
and nuclear trafficking of STAT1.  The existence of multiple viral mechanisms for 
antagonizing the induction of the host IFN response underscores how critical this 
system is in restricting VEEV infection.    
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APOPTOSIS 
Alphavirus infection of mammalian cells frequently results in apoptosis in vitro, and it 
is thought that the induction of apoptosis in infected cells in vivo plays an important 
role in determining infection outcome (136).  Much of what is known about apoptosis 
induction by alphavirus infection comes from studies of SIN infection of mouse 
neurons.  In vitro induction of apoptosis by SIN has been demonstrated to be 
dependent upon caspase activity and Ras signaling, and can be inhibited in some 
cell types by overexpression of the host anti-apoptotic protein Bcl-2 (105, 114, 178).  
Additional studies have demonstrated that the susceptibility of neurons to SIN-
induced apoptosis depends on both the strain of virus used and the age of the 
animal, with neurons from neonatal mice (≤14 days of age) being much more 
susceptible than those from weanling or adult mice (72, 73, 243).  The ability to 
induce apoptosis in adult neurons is associated with increased neurovirulence in 
mice (243).  This pattern might help explain the extreme neurovirulence of VEEV, as 
it can induce apoptosis in adult neurons in vivo as well (99).  Whether VEEV induces 
apoptosis in other in vivo cell targets, such as dendritic cells, remains unknown. 
 
The exact mechanism(s) by which VEEV is able to induce apoptosis in neurons, or 
other cell types for that matter, is not known.  SIN has been demonstrated to induce 
apoptosis in a neuronal cell line by a fusion-dependent, but replication-independent 
mechanism, suggesting that the viral glycoproteins are involved (103, 104).  Entry of 
SIN rapidly activated acidic sphingomyelinase, which in turn hydrolyzed 
spingomyelin in the plasma membrane to release ceramide, a potent inducer of 
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apoptosis (103, 183).  In fact, overexpression of acid ceramidase was sufficient to 
prevent SIN-induced apoptosis (103).  In addition to the clear effects of the viral 
glycoproteins, there is almost certainly a role for the nonstructural proteins as well, 
as mutations in nsP2 result in a virus that is incapable of inducing apoptosis in vitro 
(54).     
 
VEEV MOUSE MODEL 
Efforts to understand the pathogenesis of VEEV infection are aided by the fact that 
experimental infection of rodents closely mirrors many aspects of disease observed 
in humans and equids (66, 100).  Infection of mice with molecularly cloned VEEV 
viruses, as well as the use of non-propagating VEEV replicon particles (VRP), have 
allowed the elucidation of multiple stages in the progression of VEEV infection and 
the development of disease (4, 28, 34, 35, 148).   
 
Sub-cutaneous (s.c.) inoculation into the footpad of a mouse is used in the lab to 
mimic the bite of an infected mosquito.  Following s.c. injection, non-propagating, 
GFP-expressing VRP (GFP-VRP) were used to identify the initial targets of VEEV 
infection in vivo.  By immune-fluorescence, the first cells to be infected by VEEV, as 
determined by GFP expression, stained positive for both DEC-205 and MHC class II, 
leading Macdonald et al. to conclude that they were Langerhans cells (148). 
Langerhans cells are a skin-resident dendritic cell population that is thought to play a 
key role in surveilling the epidermis for microbial insult (13, 87, 162).  This result is 
complicated somewhat by the absence of detectable CD11c, a universal dendritic 
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cell marker, on these cells (61).  Given recent studies defining at least three distinct 
skin-resident dendritic cell populations, further work is needed to more rigorously 
define the initial targets of VEEV infection in the skin (45, 87).  Regardless, the 
MacDonald et al. study clearly showed that GFP-positive cells with a dendritic 
morphology rapidly traffic to the draining popliteal lymph node following infection, 
with infected cells appearing in the draining lymph node by 30 minutes post-infection 
(148).  This observation is in line with multiple studies describing the rapid migration 
of Langerhans and other tissue resident dendritic cell populations to draining lymph 
nodes upon encounter of microbial stimulus (85-87, 162).      
 
Following migration of infected skin-resident cells to the draining lymph node, 
subsequent rounds of viral replication rapidly lead to extremely high viral titers (up to 
107 pfu/g) being detectable by 6 hours post-infection (4, 70, 148).  The pool of lymph 
node-resident cells that are susceptible to VEEV infection remains poorly defined, 
though a fraction have been shown to be DEC-205+, suggesting that they are 
dendritic cells (148).  Efficient replication within the draining lymph node then feeds 
into a serum viremia that is detectable by 12 hours post-infection (4, 70).   
 
The development of a sufficiently high concentration (≥104 pfu/mL) of infectious virus 
within the serum is required for viral invasion of the central nervous system (CNS) 
(K. Bernard, unpublished results).  The concentration-dependence of this process 
supports the hypothesis that neuroinvasion occurs when the diffusion of infectious 
virus through the permeable tight junctions of fenestrated capillary endothelial cells 
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facilitates infection of nearby cells of the peripheral nervous system (28).  Following 
infection of peripheral nerves, VEEV is then thought to disseminate to the CNS via 
centripetal spread (28).  The anatomical site where this process is thought to occur 
most efficiently is the olfactory neuro-epithelium, a unique mucosal surface that is 
densely innervated with the dendritic cilia of olfactory sensory neurons (28, 262).  
Using in situ hybridization, Charles et al. were able to demonstrate that olfactory 
sensory neurons within the neuro-epithelium were susceptible to VEEV infection 
(28).   The axons of these cells directly synapse with CNS neurons within the 
olfactory bulb, thus providing a potential route for the virus to circumvent the blood 
brain barrier and gain entry to the CNS (262).  Chemical ablation of this tissue 
delayed entry of the virus into the CNS, but did not prevent it, indicating that CNS 
entry via olfactory nerves is merely the most efficient of multiple possible entry 
routes (28).  One of the implications of this particular mechanism is that the 
efficiency of neuroinvasion is a function of the ability of the host to control the 
amount of infectious virus present in the serum in the first 24 to 48 hours following 
infection. 
 
Once VEEV has crossed from the serum into the CNS, it replicates predominately 
within neurons (28, 70, 217).  Consistent with neuroinvasion occurring via olfactory 
sensory neurons, virus is first detectable in the CNS by in situ hybridization within 
the glomerular layer of the olfactory bulb within 30 hours of peripheral infection (28).  
The glomerular layer of the olfactory bulb is where the axons of olfactory sensory 
neurons connect with post-synaptic cells of the CNS and thus would serve as the 
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entry point for virus entering the CNS via the olfactory neuro-epithelium (195).  
Subsequent spread throughout the olfactory bulb is followed by gradual 
dissemination to other areas of the brain connected through the olfactory network, 
including the pyriform cortex, entorhinal cortex, hypothalamus, amgdala, 
hippocampus, supraoptic nucleus, cerebellum, and brain stem, by day 6 post-
infection (28, 70).   
 
The neuropathology observed in mice infected with VEEV results from a 
combination of virus-induced cell death in infected neurons as well as the 
detrimental effects of the host immune response (27).  Neuropathology following 
infection with other encephalitic alphaviruses such as Sindbis virus and Semliki 
Forest virus is predominately driven by an immunopathic host response to the virus 
(48, 117, 135).  In SCID mice, however, which lack functional B and T cells, VEEV 
infection results in extensive neuropathology, characterized by progressive 
vacuolation of the neuropil and spongiosis, which eventually results in the death of 
the animal despite the absence of inflammation (27, 149).  This suggests that VEEV 
replication alone is sufficient to induce a lethal amount of neuronal pathology.  A 
potential mechanism for this effect is provided by the observation that, unlike many 
strains of Sindbis virus or Semliki Forest virus, VEEV infection of CNS neurons in 
adult mice can trigger apoptotic cell death (27, 99, 226).  One caveat with studies 
carried out in SCID mice is that microglial and other innate immune cell populations 
are intact and might be contributing to the observed pathology. 
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In immunocompetent mice, VEEV infection of the CNS results in the development of 
neuropathology that is distinct from that observed in SCID mice (27).  By 6 days 
post-infection, large numbers of mono- and polynuclear cells are seen in 
perivascular regions as well as within the parenchyma (27).  Meningitis and 
scattered micro-hemorrhaging are also characteristic.  In studies by Charles et al., 
SCID mice infected with VEEV showed an average survival time (AST) of 8.9 ± 0.9 
days compared with immunocompetent CB17 mice which survived an average of 6.8 
± 1.2 days, demonstrating that while the direct pathology induced by viral replication 
within the CNS is sufficient to induce mortality, the effects of the host inflammatory 
response exacerbate this process.   
 
IMMUNITY TO VEEV 
Efforts to identify the host immune mechanisms required for the successful 
development of immunity against VEEV have been hampered by the extreme 
lethality of the virus in small animal models.  Our current understanding of VEEV 
immunity comes primarily from in vitro studies, mouse studies using vaccination or 
transfer of immune serum or cells, and extrapolation from SIN experiments.  
Correlates of protection in humans remain poorly understood, and no licensed 
vaccine exists for human usage. 
 
The importance of the innate immune system in controlling VEEV infection has been 
clearly demonstrated by studies examining the interaction of the virus with the type I 
IFN system in mice.  Following infection of a mouse with VEEV, large amounts of 
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IFN-α/β are detectable in the serum within six hours, though the mechanism of this 
induction remains unknown (27, 215, 260).  In mice lacking the IFN-α/β receptor, the 
AST of VEEV-infected mice is shortened significantly in the absence of an intact 
type I IFN system, to 30 hours versus 7.7 days in control mice in one study (260).  
The dramatically reduced survival time of these animals appears to result from an 
inability to control viral replication and dissemination in the periphery, resulting in 
rapid (<14 hours) entry of the virus into the CNS (260).  Additionally, treatment of 
VEEV-infected mice with pegylated IFN-α was shown to prevent mortality and 
facilitate viral clearance, demonstrating the in vivo IFN sensitivity of VEEV (147). 
 
Antiviral antibodies can act to limit viral infection by multiple mechanisms.  Antibody 
binding to virus particles can prevent them from binding or entering target cells either 
through direct steric interference with cellular receptors or indirectly by preventing 
conformational changes within the viral envelop proteins required for infectivity (77).  
Non-neutralizing antibodies can also limit viral spread by facilitating clearance of 
virus from the blood by Fc- or complement receptor bearing cells in the 
marginal/sinusoidal zones of secondary lymphoid organs (77, 184).  Finally, virus-
specific antibody can directly bind and trigger the destruction of infected cells (214).  
In the case of infection with a neuronotropic RNA virus, the production of anti-viral 
antibodies, particularly neutralizing antibodies, is thought to be the key determinant 
of immunity (71).  
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The advent of hybridoma technology facilitated the identification of antigenic sites 
within the E1 and E2 glycoproteins of VEEV (208).  Analysis of a panel of 
neutralizing and non-neutralizing monoclonal antibodies (MAb) using a combination 
of competitive-binding and neutralization-escape assays allowed the identification of 
the major neutralization domains in E1 and E2 (208, 209).  For E2, the key 
neutralization domain was reported as lying between residues 182 and 207, based 
on the location of in vitro-generated neutralization escape mutations.  Neutralizing 
anti-E1 antibodies appear to also act by obscuring this domain, as an anti-E1 
neutralizing MAb competed with neutralizing anti-E2 MAbs for binding (208).  This 
finding mirrors work with SIN that showed binding competition between anti-E1 and 
anti-E2 neutralizing MAbs (231).    
 
In vitro neutralizing activity has been shown to be highly predictive of in vivo 
protective effect in mice infected with VEEV, as well as a variety of other viruses (77, 
209).  In fact, two different neutralizing anti-E2 MAbs were shown to protect mice 
against death when administered up to 24 hours after infection with aerosolized 
VEEV, an extremely rigorous challenge (197).  Non-neutralizing MAbs have been 
demonstrated to be protective in vivo as well.  An MAb against epitope b of VEEV 
E1 exhibited no neutralizing activity in vitro, and yet was highly protective against 
extremely high doses of multiple strains of VEEV in three week old mice when given 
prior to infection (154).  This result, as well as similar results obtained with non-
neutralizing anti-SIN MAbs, underlines the fact that anti-viral antibodies can limit viral 
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infection in vivo by numerous mechanisms that are not assessed by the standard in 
vitro neutralization assay.   
 
Studies by Levine and Griffin using SIN suggested an additional mechanism by 
which anti-viral antibodies may mediate protection during encephalitic alphavirus 
infection (135).  They showed that neutralizing anti-E2 MAbs could non-cytolytically 
clear infectious virus from the CNS of SCID mice persistently infected with SIN.  
Recapitulating this effect in vitro using rat dorsal root ganglion cultures, they showed 
that MAb treatment inhibited viral protein production, though the molecular 
mechanism involved remains unknown.  Though intriguing, the strain of SIN used 
was avirulent and it remains to be seen if anti-viral antibodies can exert a similar 
effect on neurons infected with a more pathogenic virus such as VEEV.       
 
αβ T cells are thought to play a minimal role in mediating protection or recovery from 
encephalitic alphavirus infection, compared with antibody (71, 189).  In the case of 
SIN, mice deficient in αβ T cells had lower mortality rates, compared with control 
mice, indicating that αβ T cells were playing no significant role in mediating 
protection (212).  For VEEV, the literature is contradictory.  In a study by Jones, L.D. 
et al., no anti-VEEV CTL activity was detectable in the spleen or draining lymph 
node of mice infected with two different live VEEV vaccines, TC-83 and CAAR 508, 
suggesting that significant CTL activity was not induced during VEEV infection and 
was likely unimportant in mediating recovery (107).  In contrast, Paessler et al. 
demonstrated that αβ T cells were required for protection against lethal VEEV 
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challenge following vaccination with a live SIN/VEEV chimeric vaccine (190).  
Additionally, the same group showed that CD4+, but not CD8+ T cells isolated from 
mice vaccinated with the same SIN/VEEV chimera could protect αβ T cell-deficient 
mice from an otherwise lethal VEEV challenge (263).  A key difference between 
these two studies is that the conclusions of Jones, L.D. et al are based on the 
absence of data (no detectable CTL activity), while those of Paessler et al. are 
based on a positive phenotype (protection), thus making them more convincing. 
 
ANTI-VEEV VACCINES 
Despite decades of effort, there is currently no anti-VEEV vaccine licensed for use in 
humans.  Early attempts to vaccinate equids during the middle of the 20th century 
using formalin-inactivated tissue from VEEV-infected animals resulted in short-lived 
immunity, and may potentially have served as the causative agent of some 
outbreaks due to live-virus contamination of vaccine stocks (256).  In order to 
produce a more immunogenic live attenuated anti-VEEV vaccine, the virulent 
Trinidad donkey strain (TD) was serially passaged 83 times through guinea pig heart 
cells (10).  The resulting vaccine strain, TC-83, has since been shown to be safe and 
highly immunogenic in equids and is currently in use in Central and South America 
(251, 256).  In humans, TC-83 has only been approved for at-risk laboratory 
personnel under the supervision of the U.S. Army Special Immunizations Program 
due to a high rate of adverse side effects and a relatively low seroconversion rate 
(256).  In an effort to produce a safer, more immunogenic vaccine for use in 
humans, several attenuating mutations were engineered into a cDNA clone of the 
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TD strain.  The vaccine produced by this method, V3526, is safe and immunogenic 
in mice and non-human primates (50, 81, 200, 204).  Unfortunately, human clinical 
trials with V3526 revealed an unacceptably high rate of adverse side effects (152).  
Thus, the development of a safe VEEV vaccine candidate for use in humans 
remains an active area of research.       
 
USE OF VEEV REVERSE GENETICS 
The study of VEEV-host interaction has been greatly aided by the development of an 
easy to use reverse genetics system.  The system was originally developed by Davis 
et al. by generating a full-length cDNA from viral genomic RNA isolated from the TD 
strain of VEEV (37).  This cDNA was cloned into a plasmid under the control of the 
T7 promoter, for easy in vitro synthesis of full-length, infectious viral genomic RNA.  
In vitro-transcribed RNA can then be introduced into permissive cells, allowing the 
production of virus stocks.  The plasmid encoding the wild-type TD sequence was 
named pV3000, and the virus generated from pV3000-derived RNA, which should 
be genetically identical to the original TD virus, was called V3000 to indicate that it is 
clone-derived.  With the viral cDNA fixed into a stable clone, it is possible to 
introduce desired mutations into the viral sequence using standard molecular biology 
approaches, and reliably produce viral stocks that incorporate the desired genomic 
sequence.  In effect, one can use the system to mutate any site in the viral genome, 
and then precisely track the effect of that mutation on any and all aspects of virus 
biology. 
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This system was used in a series of studies to dissect the early stages of VEEV 
infection of the mouse.  These studies began with work by Johnston and Smith that 
took TD as a starting point, and then selected viral mutants that could rapidly 
penetrate baby hamster kidney (BHK) cells (106).  Those mutants that were able to 
rapidly penetrate BHK cells were then demonstrated to be avirulent in adult mice, 
compared with the parental TD virus as well as other slowly penetrating mutants.  
The attenuated mutants were sequenced, and the sequence changes, all within E2 
or E1, were then cloned either singly or in combinations into the pV3000 infectious 
clone, to yield a panel of genetically defined, attenuated VEEV mutants (36).  When 
introduced into mice by s.c. injection, these mutants exhibited defects at various 
early stages of the infection (4, 11, 34, 70, 148).  By directly linking changes in the 
viral glycoprotein sequence to specific defects in viral spread and pathogenicity, 
these mutants provided excellent tools for defining mechanisms of in vivo 
attenuation.      
  
Characterization of several of these attenuated glycoprotein mutants revealed the 
importance of heparan sulfate binding affinity as a determinant of in vivo attenuation 
(4, 11).  Four of the attenuating mutations were found to be substitutions of positively 
charged lysine for negatively charged glutamic acid (E->K) at positions 3, 4, 76, and 
209 in the E2 protein, each of which resulted in a higher affinity for negatively 
charged heparan sulfate (11).  The E76K and E209K mutations resulted in viruses 
that were unable to efficiently spread from the inoculation site or early lymphoid sites 
of replication, respectively, resulting in an absence of detectable serum viremia or 
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neuroinvasion (70).  Heparan sulfate and other related glycosaminoglycans are 
ubiquitous on the surfaces of every cell type as well as the extracellular matrix, and it 
has been hypothesized that increased affinity for heparan sulfate might limit the 
ability of a virus to disseminate in vivo (17, 121, 216).  Additionally, Bernard et al. 
showed that viruses with these mutations were more efficiently cleared from the 
blood following intravenous injection (11).  Despite showing profound defects early in 
the infection process and inducing little to no morbidity in mice, the heparan sulfate-
binding mutants replicated to a sufficient degree in vivo to generate protective 
immunity against subsequent lethal VEEV challenge (36).  This suggests that 
mutations that confer high heparan sulfate affinity should be considered as part of an 
attenuation strategy when engineering future live attenuated vaccines.   
 
Attenuated VEEV mutants have also been useful in exploring the roles of viral 
variation and selection in pathogenesis.  One example involves the mutant, V3010, 
which is identical to wild-type V3000 except for the E76K mutation in E2 that 
conveys heparan sulfate binding.  When introduced into the footpad of a mouse, 
V3010 is unable to spread efficiently from the site of inoculation or the draining 
lymph node, ostensibly due to its affinity for heparan sulfate (4, 70). In effect, the 
ubiquity of heparan sulfate was acting as a bottleneck that prevented further 
dissemination and infection.  Virus was, however, sporadically detected outside of 
the draining lymph node, and when these viruses were sequenced, they were found 
to contain reversion mutations (4).  Many of these were single-site revertants, 
containing a K76E mutation that resulted in wild-type V3000 sequence, but a 
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proportion of them were second-site revertants that maintained the lysine at position 
76 but gained an additional K116E mutation.  These revertant viruses were 
detectable by 24 hours post-infection, suggesting that VEEV was able to generate 
sufficient genetic variability within the first 24 hours of infection to overcome a potent 
host bottleneck. 
 
An infectious clone containing both the E76K and K116E mutations in the TD 
background was generated, and the resultant virus, V3533, was shown to have low 
affinity for heparan sulfate, similar to the wild-type V3000 virus (11).   Having lost the 
ability to bind heparan sulfate, V3533 was no longer subject to the early bottleneck 
that inhibited infection with the attenuated, heparan sulfate-binding mutants.  This 
was clearly demonstrated when mice were infected in the footpad with V3533.  
V3533 spread from the inoculation site to the draining lymph node to other 
secondary lymphoid organs with similar kinetics to wild-type V3000 (4).  In addition, 
V3533 infection resulted in the development of a serum viremia and viral invasion of 
the CNS, though to lower titers than V3000.  Unlike V3000, however, V3533 was 
cleared from the CNS in most infected animals, resulting in a significantly lower 
mortality rate (4).  Because of these unique properties, V3533 has been used in the 
studies described here as a model for successful recovery from VEEV-induced 
encephalomyelitis.    
 
COMPLEMENT SYSTEM OVERVIEW 
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The host complement system is an ancient network of over thirty soluble and cell-
associated proteins that can be activated by conserved molecular patterns of 
infection or injury to restrict microbial infection through multiple distinct mechanisms.  
These mechanisms range from opsonization and/or direct killing of pathogens to 
recruitment and activation of downstream cellular responses (21, 111, 210, 265).  
Predating the evolutionary split between vertebrates and invertebrates, and thus the 
development of the adaptive immune system, the complement system is considered 
part of the innate immune system (56).  However, during the evolution of the 
adaptive immune system, the complement system was co-opted to mediate 
regulatory cross-talk between the innate and adaptive systems (21).  Due to its wide 
range of effector and regulatory capabilities, the complement system appears to play 
a role in influencing every stage of the host response to viral infection.  Depending 
on the virus, the effects of complement activation can be protective or pathogenic.  
 
COMPLEMENT ACTIVATION PATHWAYS 
There are three major pathways that mediate complement activation: the classical 
pathway, the lectin pathway, and the alternative pathway.  Each of these pathways 
terminates in the formation of a C3-convertase complex that can catalyze the 
cleavage of C3.  The classical pathway is typically initiated by the binding of soluble 
C1q to complement-fixing antibody-antigen complexes, though binding of C1q by the 
C-type lectin SIGN-R1 can also activate the classical pathway in an antibody-
independent manner (109).  Each C1q molecule has six globular head domains that 
can bind the Fc portion of complement-fixing IgG and IgM.  The affinity of any single 
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globular head for an Fc portion is relatively low, so it takes the aggregation of 
several Fc portions within an immune complex to stably bind C1q (120).  Stable C1q 
binding then activates two serine proteases, C1r and C1s, that in turn cleave C4 and 
C2 to yield the C4b-C2a C3 convertase (167).  The lectin pathway is activated by 
soluble collectin proteins, primarily mannose-binding lectin (MBL) and members of 
the ficolin family (213).  These proteins act as pattern recognition receptors that bind 
specific sugar groups displayed on the surface of invading pathogens or apoptotic 
cells (53, 213).  This binding results in the recruitment and activation of the MBL-
associated serine proteases MASP-1 and MASP-2, which, similar to C1r and C1s, 
then cleave C4 and C2 to generate the C4b-C2a C3 convertase (238).  Finally, 
activation through the alternative pathway can occur independently of any 
recognition event.  Spontaneous hydrolysis of C3 produces the cleavage product 
C3b, which can indiscriminately bind to plasma membranes.  Bound C3b then 
recruits factor B, and the resultant C3bB is cleaved by the soluble serine protease 
factor D to produce the C3bBb C3 convertase.  This cascade also provides an 
amplification loop for C3 cleavage following activation through the other pathways.  
While the alternative activation cascade is capable of occuring in the absence of any 
specific recognition event, there is growing evidence that recognition of invading 
microorganisms or apoptotic cells by properdin can significantly enhance the 
efficiency of the pathway (112). 
 
COMPLEMENT CASCADE 
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All of the activation pathways converge at the cleavage of C3 into C3a and C3b.  
C3b contains a highly reactive thiolester that binds with nearby surfaces, resulting in 
rapid opsonization.  This opsonization process can occur extremely rapidly, as up to 
107 C3b molecules can be deposited within 5 minutes under ideal conditions (186). 
Further cleavage of C3b by factor I produces iC3b, C3c, C3d, and C3g (111).  Newly 
produced C3b can bind to either of the C3 convertases, C3bBb or C4bC2a, and 
convert them into C5 convertases, C3bBbC3b and C4bC2aC3b, that can efficiently 
cleave C5 into C5a and C5b.  C5b production initiates the terminal complement 
cascade, in which C5, C6, C7, C8, and C9 are recruited to form the membrane 
attack complex (MAC) (111).  
 
EFFECTOR MECHANISMS 
One of the best studied anti-viral effects of the complement system is its ability to 
enhance the ability of antibodies to reduce viral infectivity. This effect has been 
demonstrated with a variety of RNA and DNA viruses, though the exact mechanisms 
remain poorly understood (33, 142, 163, 233).  Suggested mechanisms include 
MAC-mediated lysis of viral particles, C1q-mediated enhancement of antibody 
avidity, and steric hindrance of entry resulting from opsonization.  In the case of 
parainfluenza virus or HIV, complement can reduce infectivity of antibody-bound 
virus through direct virolysis, probably due to MAC formation (225, 245).  For 
vaccinia virus, West Nile virus, and influenza A virus, the neutralization-
enhancement effect of complement was mediated by the coating or opsonization of 
viral particles, rather than virolysis (9, 49, 160).  In the case of West Nile virus, the 
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presence of C1q was shown to reduce the number of bound antibody molecules 
required to neutralize a virion particle, potentially through a steric hindrance 
mechanism (160).  Complement-mediated enhancement of neutralizing antibody 
activity may play a key role in controlling infection by limiting viral dissemination and 
spread from early sites of replication (169, 184).    
 
The complement system also acts to limit viral dissemination through antibody-
independent mechanisms.  At least seven distinct complement receptors (CR1, 
CR2, CR3, CR4, C1qR, CRIg, and SIGN-R1) have been identified as binding and 
facilitating clearance of complement component-bound pathogens from the blood 
(64, 90, 94, 109, 111, 122).  These receptors are expressed by macrophage and 
dendritic cell populations at sites of blood and lymph filtration, such as the liver, 
splenic marginal zone, and the subcapsular sinus of lymph nodes.  Collectively, 
these receptors can bind and trigger the phagocytosis of viruses or cell debris 
opsonized by MBL, C1q, C3b, iC3b, or C4b.  In addition to clearing virus from 
circulation, complement receptor-mediated uptake can also result in efficient 
presentation of viral antigen to B cells.  This effect has been shown to be required 
for maximal antibody induction during infection with both VSV and influenza A virus 
(68, 108).  
 
The complement cascade produces several cleavage products that act to recruit 
innate immune cells to sites of complement activation.  The cleavage of C3, C4, and 
C5 during the complement cascade results in the production of the anaphylatoxins 
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C3a, C4a, and C5a.  These protein fragments act through the receptors C3aR and 
C5aR to recruit inflammatory cells such as neutrophils, macrophages, and dendritic 
cells to sites of complement activation (32, 74, 157, 181, 250).  Signalling through 
C3aR and C5aR, as well as other complement receptors such as CR3, can also 
enhance the activation and effector function of NK cells, macrophages, neutrophils, 
and eosinophils (138, 165, 181, 211).  The roles of these receptors in the context of 
viral infection have been poorly studied, though that is beginning to change.  
Morrison et al. recently showed that the majority of the pathology observed following 
Ross River virus infection was dependent upon CR3 expression and its role in 
regulating the activation of tissue-infiltrating inflammatory cells (168).   
 
In addition to its role during the innate response to viral infection, host complement is 
an important regulator of the T cell response, both through effects on antigen 
presenting cells (APC) as well as directly on T cells (111).  Maximal T cell responses 
to West Nile virus, influenza A virus, and lymphocytic choriomeningitis virus (LCMV) 
have all been shown to be dependent upon complement activation (125, 159).  
Release of C3a and C5a can induce the migration of APC populations, such as 
dendritic cells, to sites of infection (224, 259).  APCs express a range of complement 
receptors and can thus respond to the presence of MBL, C1q, C3b, and C4b bound 
to antigen at the site of infection (145, 166).  In fact, C1q and C3 were shown to be 
essential for optimal antigen uptake and maturation by dendritic cells (24, 101).  
Additionally, signaling through C3aR, C5aR, and/or CD46 (recognizes C3b and C4b) 
can either positively or negatively modulate IL-12 production by APCs, depending on 
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the model and specific cell population, thus affecting the Th1-Th2 skew of the 
downstream T cell response (42, 84, 110).   
 
As is the case with different APC populations, C5a can attract T cells to sites of 
complement activation (177).  While signaling through the primary complement 
receptors, CR1, CR2, CR3, and CR4, does not appear to play a significant role in 
directly regulating mouse T cells, signaling through the complement regulatory 
receptors CD46, CD55, and CD59 during priming can modulate downstream 
proliferation and effector phenotype (5, 88, 113, 146).  CD59 signaling in particular 
was shown to significantly blunt the CD4+ T cell response to vaccinia virus (146).             
 
Finally, the complement system has been demonstrated to promote the induction of 
anti-viral antibody responses through several mechanisms (21).  B cells express 
both CR1 and CR2, and signaling through these receptors following uptake of 
antigen coated with C3b, iC3b, C3d, or C4b synergizes with B cell receptor 
signaling, thus lowering the threshold for B cell activation (22).  CR1/CR2 expression 
by follicular dendritic cells is thought to enhance antibody induction through retention 
of complement-coated antigen within the B cell follicle (8).  During West Nile virus 
infection, CR1/CR2 signaling is absolutely required for the induction of a protective 
antibody response, though it remains unclear what CR1/CR2-dependent 
mechanisms are important (161).  CR1/CR2 expression, along with myeloid cell-
derived C3, was also required for the humoral response to herpes simplex virus 
(HSV) infection (31, 247).  In contrast, during influenza A virus infection, CR1/CR2 
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signaling was dispensable for virus-specific IgG production, though complement-
dependent priming of CD4 T cells was required, demonstrating the potential 
importance of indirect effects of complement on B cell function (125).  Additionally, 
the capture of viral particles by SIGN-R1 expressed by dendritic cells within the 
lymph node medulla was also recently shown to be important for the humoral 
response to influenza A virus, though it remains to be seen whether this effect is 
dependent upon complement activation (68). 
            
OVERVIEW OF CNS IMMUNITY 
The CNS has long been considered an “immune-privileged” site based on the 
scarcity of immune cells within the brain and spinal cord parenchyma, as well as the 
exclusion of circulating immune cells and soluble mediators by the blood brain 
barrier (BBB).  Studies demonstrating the rapidity of the response to infection within 
the brain, as well as systemic inflammatory signals, have made clear that the CNS is 
not immunologically inert (25, 78, 129, 202).  Instead, the CNS is uniquely regulated 
in order to facilitate control of infection while maintaining the functional integrity of a 
delicate and vital tissue (71, 206, 227).  
 
RESTING STATE 
There are four major cell types present within the CNS parenchyma, though further 
functional subdivision is probable.  Neurons are the essential cells responsible for 
transmitting and processing electrical signals within the CNS.  For the most part, 
these cells are terminally differentiated and not easily replaced, thus the protection 
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of individual cells from infection-associated damage is important for maintaining host 
viability (143).  Neuronal viability is sustained by three major supporting cell 
populations: astrocytes, oligodendrocytes, and microglia.  Astrocytes help maintain 
neuronal health by producing various neuroprotective factors and metabolizing 
excess neurotransmitters and toxins.  They also play a role in regulating the integrity 
of the BBB (237).  Oligodendrocytes are responsible for producing the myelin 
sheathing that insulates neuronal axons and enhances electrical signal conduction.  
Microglia are macrophage-lineage cells that serve as the primary immune cells of 
the CNS (78).  In the resting state, these cells remain mostly stationary, constantly 
scanning the surrounding environment with long, highly mobile processes (180).  It is 
through this scanning process that microglia are able to rapidly detect and initiate 
the response to infection or other distress. 
 
The generally immune-suppressive environment within the CNS is maintained 
through several mechanisms.  Within the parenchyma, microglia are normally 
maintained in a resting state by constitutive interaction with healthy neurons via the 
ligand-receptor pairs CD200-CD200R, CX3CL1-CX3CR1, and SIRPα-CD47 (78, 93).  
Expression of major histocompatibility complex (MHC) molecules is low to 
undetectable, especially on neurons, in the absence of inflammation (117, 240).  In 
addition, several other factors, such as TGF-β and various gangliosides and 
neurotrophins, are constitutively produced by astrocytes and neurons and help 
suppress inflammation (46, 71).  Glucocorticoids released from the adrenal cortex 
can antagonize IRF-3-, TBK1-, and NF-κB-dependent pro-inflammatory signaling 
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through multiple mechanisms (175, 182, 185).  Under normal conditions, most 
immune cells are excluded from entering the CNS from circulation by a combination 
of BBB-mediated exclusion and the low level of adhesion molecule expression by 
CNS endothelial cells (7, 91).  The BBB mainly consists of specialized tight junctions 
between CNS endothelial cells, supported and regulated by the end-feet structures 
of perivascular astrocytes (7).  These specialized tight junctions normally prevent the 
entry of cells, cytokines, antibodies, viruses, and other large hydrophilic bodies from 
the blood.  This exclusion is not absolute, as activated T cells can cross the intact 
BBB during normal surveillance, partially though the expression of P-selectin by the 
CNS endothelium (20, 92).  The impermeability of the BBB is not uniform, however, 
as permeability is much higher in certain regions of the brain involved in regulating 
the autonomic nervous and endocrine systems, specifically the circumventricular 
organs and choroid plexus (7).  The enhanced permeability in these regions allows 
CNS-resident cells to detect and respond to some systemic inflammatory signals, 
and suggests that the immuno-regulatory environment may differ between different 
regions of the CNS (129).       
 
IMMUNE INDUCTION 
Despite the immuno-suppressive environment, CNS-resident cells are capable of 
quickly responding to viral infection. A variety of pattern recognition receptors (PRR) 
are expressed with the CNS, including those that recognize signs of viral replication, 
such as toll-like receptors (TLR) and RIG-I-like receptors (RLR) (206, 236).  Viral 
infection causes neurons to rapidly produce IFN-β through both TLR3- and RLR-
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dependent pathways (201, 236).  The CNS is unique in that IFN-β, rather than IFN-
α, is the predominant type I IFN produced in response to infection (71).  This may be 
due to the fact that IFN-β appears to have neuro-protective effects in vivo, while IFN-
α is highly toxic to neurons (2, 14, 156).  Microglia can be activated in response to 
viral infection either by direct sensing of virus associated PAMPs or complement 
activation, loss of CD200R or CX3CR1 signaling due to neuronal distress, or by 
cytokines produced by other activated microglia or astrocytes (26, 93, 176, 187).  
Activated microglia upregulate surface expression of MHC class I and II, and can 
express a number of pro-inflammatory cytokines, depending on the specific virus 
infection, including IL-1, IL-6, IL-12, TNFα, MIP1β, MCP1, MCP3, RANTES, and 
IP10 (71, 117, 199).  The production of pro-inflammatory cytokines by CNS resident 
cells can rapidly override many of the immune-suppressive factors that protect the 
CNS.  Inflammation within the CNS can induce an increase in permeability of the 
BBB, as well as increased expression of adhesion molecules such as ICAM1 and 
VCAM1 on the CNS endothelium, facilitating entry of immune cells from circulation 
(3, 196, 253).  Exposure to type I and type II IFN induces neurons to express MHC 
class I (179). 
 
REGULATION OF CNS IMMUNE RESPONSES 
Another attribute of the CNS that has contributed to its description as 
immunologically inert is the lack of lymphatic drainage from the CNS parenchyma 
(228).  This is most likely of little consequence, as all viral infections are initiated in 
the periphery prior to neuroinvasion, and thus the adaptive response would be 
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primarily initiated in the lymph nodes draining those early sites of replication.  Once 
the BBB has been opened by CNS inflammation, circulating innate effector cells, as 
well as adaptive lymphocytes primed in the periphery, are free to enter the CNS 
parenchyma and traffic to sites of infection and inflammation.  Usually, the first 
inflammatory cells to enter the CNS from the periphery are myeloid-lineage, 
inflammatory monocytes, characterized as CD11b+ Ly6c+ MHC class II+, typically 
within a few days of infection (63, 71, 116).  The recruitment of these cells is 
dependent upon MCP1-CCR2 signaling, with possible additional roles for CCR5, 
TNFα, and IL-23 (65, 126, 220, 239).  The cells within this population most likely 
exhibit some phenotypic variation, and have been described as playing either 
pathogenic or protective roles depending on the specific virus infection (63, 116, 
239).  Within the CNS, these cells likely function as they do elsewhere in the body, 
secreting pro-inflammatory cytokines, clearing cellular debris, and regulating the 
activity of other infiltrating cell populations. 
 
B and T cells appear later, following priming in the periphery.  Not much is known 
about CNS-specific regulation of B cells during viral infection.  In the case of mouse 
hepatitis virus (MHV) infection, CNS-infiltrating B cells showed a delay in the onset 
of antibody secretion, compared with peripheral B cells, suggesting some CNS-
specific regulation (241).  Virus-specific, antibody-secreting B cells are retained 
within the CNS parenchyma long after infectious virus has been cleared (241, 242).  
CNS-specific regulation of the T cell response has been more thoroughly examined.  
The abundance of gangliosides within the CNS can inhibit T cell responses at the 
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level of antigen presentation, by inhibiting MHC class I and II expression by 
astrocytes (153).  More importantly, exposure to gangliosides inhibits NF-κB 
activation and Rb phosphorylation within T cells, resulting in an inability to produce 
IL-2 and limited ability to survive and proliferate (97).  This effect was demonstrated 
in the context of SIN infection where T cells isolated from the brain, but not the 
spleen, were incapable of producing IL-2, an effect recapitulated in vitro using brain-
derived lipids (98).  Microglia may also play a role in restricting T cell IL-2 production 
and proliferation, as T cells primed ex vivo by primary microglia, but not other APC 
populations, exhibit defects in IL-2 production, proliferation, and survival (52).  In 
addition to the effects of gangliosides on T cell survival and proliferation, neurons 
constitutively express FasL, which can trigger apoptosis in Fas-expressing activated 
T cells (51, 158).  Given the potential destructive effects of activated T cells, it is 
likely that additional mechanisms of control remain to be described. 
 
CLEARANCE FROM NEURONS  
Infection of CNS neurons with a cytopathic virus presents a unique problem to the 
host.  These cells are essential for host function, and yet are for the most part 
irreplaceable (143).  As a result, the immune response must curtail viral replication 
and spread without destroying the infected cells in the process.  This requirement 
should preclude the widespread use of standard cytolytic methods of viral clearance, 
such as CTL-mediated cell killing.  As a consequence of this limitation, “clearance” in 
many cases may result from a host-mediated shutdown of viral replication within 
infected cells, rather than a total eradication of all viral protein and nucleic acid.  
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Support for this possibility comes from numerous studies in which viral RNA or 
antigen was found to persist for long periods of time within the CNS following 
apparent clearance of infectious virus (40, 83, 151, 242).   
 
Host strategies for mediating neuronal clearance differ somewhat between different 
viruses, and are probably partially dependent upon the specific biology of the virus in 
question (71).  As described earlier, studies using SIN have suggested an important role 
for virus-specific antibody in mediating non-cytolytic clearance of virus from neurons 
(135).  A similar effect has been described during rabies virus infection (95).  For many 
neuronotropic viruses, including Borna disease virus, Theiler’s murine 
encephalomyelitis virus, SIN, MHV, and measles virus, clearance appears to be 
primarily mediated by the effects of T cell-delivered IFNγ (12, 82, 192, 193, 207).  In the 
case of vesicular stomatitis virus, inducible nitric oxide might also play a role (124).  In 
these models, IFNγ appears to block viral replication while maintaining the viability of 
the infected neurons, though the exact molecular mechanisms by which IFNγ signaling 
exerts these effects remain unclear.  Interestingly, different CNS neuron populations 
vary in their sensitivity to the anti-viral effects of IFNγ.  Following SIN infection, spinal 
cord motor neurons, but not cortical neurons in the brain, were susceptible to IFNγ-
mediated clearance (12).   
 
Recent studies with SIN have suggested a role for autophagy in neuronal clearance 
(188).  Autophagy is a cellular process in which intracellular material is packaged within 
double-membrane enveloped structures that are then targeted to the autolysosome for 
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destruction (137).  This pathway has been shown to be critically involved in cellular 
survival, development, carcinogenesis, and host defense (39, 137).  Orvedahl et al. 
showed that mice in which the autophagy pathway has been inactivated by an induced 
deletion in the essential Atg5 gene are defective in their ability to clear SIN from 
neurons, resulting in a higher mortality rate (188).  They went on to show that the SIN 
capsid protein interacted with the cellular protein p62, an adaptor protein that targets 
cytosolic proteins for autophagic degradation.  IFNγ signaling has previously been 
demonstrated to induce autophagy in macrophages (80, 96).   It will be interesting to 
see if the same is true in neurons, possibly providing a specific mechanism for the 
antiviral effects of IFNγ signaling in neurons.   
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CHAPTER 2: 
EARLY INTERACTIONS WITH THE HOST COMPLEMENT SYSTEM DETERMINE 
DOWNSTREAM DISEASE OUTCOME FOLLOWING VENEZUELAN EQUINE 
ENCEPHALITIS VIRUS INFECTION 
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ABSTRACT 
Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne RNA virus of the 
genus Alphavirus that is responsible for a significant disease burden in Central and 
South America through sporadic outbreaks in human and equid populations.  In 
mice, the virus initiates a biphasic disease course in which initial replication within 
lymphoid tissue seeds a serum viremia that in turn facilitates virus invasion of the 
CNS.  Replication within CNS neurons leads to a paralyzing, consistently lethal 
encephalomyelitis due to the combined detrimental effects of virus-mediated 
cytopathology and the host inflammatory response within the brain.  The host 
complement system is capable of playing both protective and pathogenic roles 
during viral infection.  In order to ascertain the role that complement plays in 
resolving VEEV-induced encephalomyelitis, we infected complement deficient C3-/- 
mice with a VEEV mutant (V3533) that causes mild, transient disease in immune-
competent mice.  In the absence of a functional complement system, peripheral 
inoculation with V3533 induces a much more severe encephalomyelitis, 
characterized by substantial weight loss, ataxia, and hind limb paresis.  This 
enhanced pathology is associated with a delay in clearance of infectious virus from 
the serum and more rapid invasion of the CNS in C3-/- mice, despite the presence of 
an intact anti-VEE antibody response.  If V3533 is directly inoculated into the brain, 
however, disease outcome in wild-type and C3-/- mice is identical.  These results 
indicate that early interactions of VEEV with the host complement system in the 
periphery can have dramatic effects on downstream disease outcome.
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INTRODUCTION 
Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne alphavirus that is 
endemic to Central and South America (18).  Though normally maintained in an 
enzootic transmission cycle between various rodent host species and the Culex 
mosquito vector, VEEV periodically emerges from its natural cycle to cause local 
epidemics in human and equid populations (57).  The most recent major outbreak 
occurred in 1995 in Columbia and Venezuela, where 75,000 to 100,000 human 
cases were reported (59).  VEEV infection in humans causes a spectrum of disease 
that ranges from asymptomatic to mild, flu-like illness to overt encephalomyelitis, 
with an overall case mortality rate of about 0.5-1% (58).  In equid populations, the 
development of overt encephalomyelitis is more common, and the overall mortality 
rate often exceeds 50% (56).  Though specific viral sequence determinants 
associated with epidemic emergence have been identified, outbreaks remain 
unpredictable (1).  As a result, VEEV remains a significant public health threat in the 
region.      
 
Much of our current understanding of VEEV pathogenesis and immunity comes from 
studies carried out in a well-characterized mouse model of infection.  VEEV infection 
of the mouse closely replicates many aspects of infection in humans and equids 
(15).  Subcutaneous injection of VEEV into a mouse  
is followed by efficient replication in the skin-draining popliteal lymph node and rapid 
dissemination to other secondary lymphoid organs (2, 35).  Replication at these sites 
leads to the development of a serum viremia within the first 12 hours of infection.  
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Viral invasion of the CNS first occurs through the olfactory neuro-epithelium, a 
mucosal surface that is densely innervated with olfactory sensory neurons (9).  It is 
thought that these cells are infected following diffusion of virus through the 
permeable tight junctions of adjacent capillaries.  The virus then disseminates into 
the olfactory bulb of the brain by centripetal spread, usually within 36 hours of 
infection (9).  Once the virus has crossed into the CNS, it replicates predominately 
within neurons, triggering the death of the animal from a paralyzing 
encephalomyelitis within 6 to 8 days post-infection (8, 17).  The mortality rate in mice 
is 100%, and results from a combination of virus-mediated cytolysis of infected 
neurons and the detrimental effects of the host immune response within the CNS (8, 
56). 
 
Engagement of both the innate and adaptive arms of the immune response are 
required for successful control of VEEV infection.  The type I interferon (IFN) system 
plays a critical role in limiting early viral replication and dissemination (60).  In mice 
with a genetic deficiency in this system, VEEV invades the CNS much earlier, 
resulting in a dramatically shorter time to death, compared with control mice.  Anti-
viral antibodies can limit viral dissemination in the periphery, as well as aid in 
clearance of virus from infected neurons (33, 37).  The role of αβ T cells during 
VEEV infection is unclear, as they can contribute both to control of VEEV infection 
within the CNS, as well as VEEV-induced immune-pathology (4, 8, 49).  Further 
efforts to identify the components of a successful immune response to VEEV 
infection have been limited by the extreme lethality of the virus in mice. 
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The host complement system is a complex network of over 30 soluble and cell-
associated factors that contribute to both innate and adaptive control of microbial 
infection (6).  Activation of the complement system in response to infection or injury 
can occur through three major pathways, classical, lectin, and alternative, all of 
which result in the cleavage of the complement factor C3.  C3 cleavage products act 
to limit infection through a number of mechanisms ranging from opsonization and/or 
direct killing of pathogens to recruitment and regulation of innate and adaptive 
effector cells (6, 29, 51).  Complement plays a critical protective role during infection 
with a number of viruses, including influenza A virus, West Nile virus, ectromelia 
virus, and herpes simplex virus (32, 39, 45, 54).  In contrast, complement activation 
enhances virus-induced pathology following infection with the alphaviruses Ross 
River virus and Sindbis virus (22, 43). 
 
In this study, we used an established model of acute, non-lethal VEEV infection to 
ascertain the role of the complement system in VEEV pathogenesis and immunity.  
Sub-cutaneous infection of wild-type C57BL/6 mice with the V3533 strain of VEEV 
results in the development of a mild febrile illness with minimal signs of CNS 
complications.  In contrast, infection of complement deficient C3-/- mice with V3533 
resulted in the development of a severe encephalomyelitis, suggesting that the 
complement system plays an important role in limiting VEEV-induced pathology.  No 
differences in disease outcome were observed following intracranial infection, 
however, indicating that complement was acting at a step prior to neuroinvasion.  
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Further studies revealed delayed serum clearance and earlier neuroinvasion in C3-/- 
mice that could not be explained by defects in inflammatory cell recruitment or anti-
VEEV antibody induction.  Together, these results demonstrate that early 
interactions with the host complement system can have profound effects on 
downstream disease outcome. 
 
MATERIALS AND METHODS 
Viruses 
The isolation of the V3533 mutant of VEEV, as well as the generation of the pV3533 
molecular clone has been described previously (2).  Virus stocks of V3533 were 
generated by in vitro transcription from a linearized plasmid, pV3533, which encodes 
the full-length V3533 cDNA, using a T7-specific mMessage mMachine in vitro 
transcription kit (Ambion).  In vitro-generated transcripts were then electroporated 
into BHK-21 cells using a Bio-Rad electroporator as described previously (2, 12).  
Culture supernatants were harvested 18 hours after electroporation, clarified by 
centrifugation at 3000 rpm for 20 min, and stored as single use aliquots at -80° C.  
Viral titers were determined by standard plaque assay on BHK-21 cells, as 
previously described (53). 
Mouse studies 
C3-/- and µMT mice (both on the C57BL/6J background) were obtained from The 
Jackson Laboratory (Bar Harbor, ME) and bred in house under specific pathogen-
free conditions. C57BL/6J mice were purchased from The Jackson Laboratory as 
needed.  All experimental manipulation of mice was performed in a biosafety level 3 
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animal facility following a 7 day acclimatization period.  For infections, 6-10 week old 
female mice were anesthetized via intra-peritoneal (i.p.) injection with a mixture of 
ketamine (50 mg/Kg body weight) and xylazine (15 mg/Kg body weight) and then 
inoculated either in the left rear footpad with 106 PFU of virus in diluent [phosphate 
buffered saline (PBS) + 1% donor calf serum, Ca2+, Mg2+] for sub-cutaneous (s.c.) 
infections, or directly into the brain with 103 PFU of virus in diluent for intracranial 
(i.c.) infections.  Mock-infected mice received diluent alone.  Weight loss and 
disease score were assessed daily in infected animals.  The scale used for disease 
scoring was as follows: (0) no signs; (1) hunched posture; (2) mild motor 
dysfunction, altered gait; (3) moderate motor dysfunction, ataxia; (4) hind limb 
paresis; (5) hind limb paralysis; (6) moribund.  Mice that lost more than 35% of their 
starting weight or became moribund were euthanized according to UNC Institutional 
Animal Care and Use Committee guidelines.  
Virus titers 
To assess VEEV titers in vivo, infected mice were sacrificed, bled, and then 
perfused through the heart with 10 mL of PBS.  Spleen, draining popliteal lymph 
node, brain and spinal cord were then removed, weighed, and frozen at -80°C in 
diluent.  Tissues were thawed, homogenized, and used to infect BHK-21 cells in a 
standard plaque assay.  
Antibody analysis 
VEEV-specific IgG and IgM levels were assessed by standard indirect ELISA.  
Purified, intact VEEV particles (2.5 µg/mL) were used to coat 96-well NUNC 
Immulon 4HBX plates (Thermo Scientific) overnight at 4˚C.  After washing, plates 
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were incubated with serial dilutions of heat inactivated mouse serum + 10% Sigma 
Blocking Buffer (Sigma) overnight at 4˚C.  Plates were washed again, incubated with 
HRP-conjugated goat anti-mouse IgM or IgG (Southern Biotech) for 2 hours at 4˚C, 
and then developed using o-phenylenediamine dihydrochloride tablets (Sigma) in 
equal parts 0.1M citric acid and 0.1M sodium citrate.  Development proceeded for 30 
minutes before the reaction was terminated with 0.1M NaF.  The OD450 values were 
measured using a FLUOstar Omega microplate reader with Omega software v1.02 
(SPSS, Inc.).  Log10 half-maximum ELISA titers were calculated using GraphPad 
Prism software v5.0 (GraphPad) and represent the log of the reciprocal dilution at 
which the half-maximum absorbance values were achieved. 
   
To assess anti-VEEV neutralizing activity, serum was collected and either left 
untreated or heat inactivated at 56˚C for 1 hour.   Serum was then diluted in diluent 
and coincubated with gfp-expressing VEEV viral replicon particles [gfp-VRP, 
described in (50)] for 1 hour at 37˚C.  VRP-serum mixtures were then used to infect 
BHK-21 cells.  18 hours post-infection, infected cells were harvested by 
trypsinization, washed, and fixed with 2% paraformaldehyde in PBS and analyzed 
on a CyAn flow cytometer using Summit 5.2 software (Dako).  IC50 titers were 
calculated using GraphPad Prism software v5.0 (GraphPad) and represent the log of 
the reciprocal dilution at which 50% inhibition of infectivity was achieved. 
Flow Cytometry 
Mock- and V3533-infected mice were sacrificed by exsanguination and perfused 
with PBS.  Draining popliteal lymph nodes were harvested, minced, and then 
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incubated for 30 minutes with shaking at 37°C in digestion media [RPMI, 1% fetal 
calf serum, 25mM HEPES, 1 mg/mL Collagenase A (Roche)].  Homogenates were 
then passed through a 40 µm strainer, washed with media, and the absolute number 
of live cells in each sample was then determined by trypan blue exclusion.  Cells 
were washed in flow cytometry wash buffer (1 x Hank’s balanced salt solution, 1% 
fetal calf serum, 0.1% sodium azide) and then stained with the following antibodies: 
anti-CD11c-PE-Texas red (Invitrogen), anti-Ly6G-FITC (clone 1A8), anti-B220-FITC, 
anti-CD3ε-PE, anti-Gr1-PE, anti-CD49b-APC, anti-MHC class II-APC, anti-CD11b-
PE-Cy7 (all eBioscience). Following staining, samples were washed, fixed in 2% 
paraformaldehyde in PBS and analyzed on a CyAn flow cytometer using Summit 5.2 
software (Dako).  Absolute numbers of each specific cell type were calculated by 
determining the number of total live cells within a sample by trypan blue exclusion 
and then multiplying that number by the percentage of live cells within the sample 
bearing the appropriate surface staining profile. 
IFN Bioassay 
Total amounts of biologically active type I IFN were determined by bioassay as 
described previously (11).  Briefly, murine L929 cells were plated in 96-well plates.  
Experimental samples, as well as IFN standards of a known IU/mL concentration 
(Chemicon), were acidified to pH=2 overnight, neutralized to pH=7.4, and then UV-
inactivated for 10 minutes.  Samples were then added to L929 cells in serial 2 fold 
dilutions.  After 24 hours of incubation, cells were infected with 2 x 105 pfu of 
encephalomyocarditis virus (EMCV).  24 hours later, the sample dilution that 
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protected 50% of L929 cell culture from EMCV-induced cytopathic effect was 
determined and compared to the IFN standard to determine the IU/mL value.   
 
RESULTS 
C3-/- mice develop more severe encephalomyelitis following V3533 infection 
Previous work has demonstrated that sub-cutaneous infection of C57BL/6 mice with 
V3533 results in the development of mild disease, associated with viral 
neuroinvasion and replication within the CNS, followed by clearance and recovery 
(4).  Using V3533 infection of C57BL/6 mice as a model of successful control of 
VEEV infection, we used complement deficient C3-/- mice to ask what role, if any, the 
host complement system played during VEEV infection.  C3-/- and C57BL/6 mice 
were infected with 106 pfu of V3533 sub-cutaneously in the footpad.  Over the first 4 
days, both mouse strains responded similarly, with a slight loss of weight but no 
other outward signs of disease.  By day 6 post-infection, however, responses in C3-/- 
and C57BL/6 mice began to diverge (Fig. 1.1).  Weight loss in C57BL/6 mice was 
minimal, and clinical signs of disease were mild, consisting of hunched posture, 
ruffled fur, and mild motor dysfunction in a subset of infected animals.  In contrast, 
C3-/- mice uniformly lost significantly more weight, and developed more severe signs 
of encephalomyelitis, with all infected animals developing pronounced ataxia and in 
some cases, hind limb paresis or paralysis.  In both C57BL/6 and C3-/- mice these 
signs of disease were transient, however, and all mice infected went on to recover.  
The significantly enhanced severity of encephalomyelitic disease observed in  C3-/- 
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mice compared with C57BL/6 clearly demonstrated that the host complement 
system was playing a protective role during V3533 infection. 
 
Enhanced disease severity in C3-/- mice is associated with more extensive 
inflammation and pathology within the brain 
VEEV-induced encephalomyelitis in mice is associated with extensive inflammatory 
cell infiltration within the brain parenchyma (8).  To determine whether the 
differences in weight loss and clinical course of wild-type and C3-/- mice following 
V3533 infection correlated with differences in inflammation and neuropathology 
within the brain, we examined H&E stained brain sections from V3533-infected mice 
(Fig. 1.2).  In both wild-type and C3-/- mice, comparable amounts of inflammatory cell 
infiltration were apparent within the olfactory bulb and meninges by day 4 post-
infection.  By day 6 post-infection, when weight loss and clinical signs began to 
diverge between wild-type and C3-/- mice, focal and diffuse inflammation were 
observed in the cerebellum and brain stems of C3-/-, but not wild-type mice.  
Inflammation was associated with occasional micro-hemorrhaging.  Inflammatory 
foci were occasionally observed within the cerebellum and brain stems of wild-type 
mice by day 8, though these were not nearly as extensive as those observed in C3-/- 
mice (data not shown).  In all V3533-infected mice examined inflammation and 
observable neuropathology were limited to the olfactory bulb, meninges, cerebellum, 
and brain stem.  Thus, the differences in outward disease signs between wild-type 
and C3-/- mice following V3533 infection correlated with the extent and severity of 
inflammation within the cerebellum and brain stem. 
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Viral burdens within the CNS of C3-/- mice are higher and less variable than 
those of wild-type mice 
V3533 infection of C57BL/6 mice results in viral replication within the brain and 
spinal cord, followed by clearance of infectious virus by day 8 post-infection.  Given 
the differences in disease outcome between C57BL/6 and C3-/- mice following 
V3533 infection, we next asked whether the more severe disease in C3-/- mice was 
associated with a larger viral burden within the CNS or a defect in viral clearance.  
To answer this question, C57BL/6 and C3-/- mice were infected s.c. in the footpad 
with 106 pfu of V3533, animals were sacrificed at 0.5, 1, 2, 4, 6, and 8 days P.I., and 
viral burdens in serum, spleen, draining popliteal lymph node, brain and spinal cord 
by were assessed by plaque assay (Fig. 1.3).   
 
In C57BL/6 mice, virus was first detected in the brain at day 2, with peak titers being 
reached between day 4 and day 6.  At day 4 titers were highly variable, ranging from 
below the limit of detection up to 106 pfu/g, but by day 6 titers were much more 
consistent, with a mean of about 104 pfu/g.  In the spinal cord, virus was detectable 
only on days 4 and 6, with no virus being detectable in a subset of mice at each 
time-point (2/9 at day 4, 3/7 at day 6).  In both brain and spinal cord, infectious virus 
was undetectable by day 8.  In contrast, C3-/- mice had detectable virus in both the 
brain and spinal cord within 24 hours of infection.  Viral titers in both tissues peaked 
at day 4, with mean titers in both brain and spinal cord significantly higher than those 
observed in C57BL/6 mice (p<0.05, Mann Whitney).  Viral titers in the brains of C3-/- 
  90 
mice at day 4 were also much less variable than observed in C57BL/6 mice, as all 
mice tested had titers of at least 105 pfu/g.  Clearance kinetics were similar between 
C57BL/6 and C3-/- mice, though at day 8, some C3-/- animals still had detectable viral 
titers in the brain (4/7) and spinal cord (1/7).  Thus, the more severe disease 
observed in C3-/- mice was associated with more rapid neuroinvasion, and higher 
and more consistent viral burdens within the CNS. 
 
C3-/- mice exhibit delay in viral clearance from the serum relative to wild-type 
mice 
To assess the effect of host complement on early replication of V3533 in the 
periphery, we compared viral burdens within the serum of C57BL/6 and C3-/- mice, 
as well as the draining popliteal lymph node and spleen, two anatomical sites of 
replication thought to contribute to serum viremia (Fig 1.3).  In the serum, peak titers 
in both C57BL/6 and C3-/- mice occurred at 12 hours post-infection and were similar, 
but clearance kinetics were quite different.  Serum titers in C57BL/6 were reduced 
about 10-fold between 12 and 24 hours post-infection, and by day 2 virus was 
undetectable in all but one animal tested.  In contrast, C3-/- mice sustained 
significantly higher serum titers at days 1 and 2 compared with C57BL/6, and virus 
was still detectable in 3 of 6 animals at day 4.  In both lymph node and spleen of 
both mouse strains, viral titers were statistically indistinguishable, except for the 
spleen at day 1 where the mean titer was actually higher in C57BL/6 mice.  Though 
not achieving statistical significance, mean titers in C3-/- mice trended higher in the 
draining lymph node at all times tested and in the spleen at days 2 and 4.   
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Host complement plays no significant protective role following intra-cranial 
introduction of V3533 
Given that C3-/- mice were deficient in their ability to control V3533 in both the 
periphery and the CNS, it was possible that the effect of host complement that 
resulted in reduced neuropathology could be occurring prior or subsequent to viral 
invasion of the CNS.  In order to address where in the infection process host 
complement was acting to limit pathology, we introduced 103 pfu of V3533 directly 
into the CNS of C57BL/6 and C3-/- mice by i.c. injection.  By circumventing peripheral 
infection, we were able to directly assess the importance of host complement within 
the CNS.  Following i.c. infection, both C57BL/6 and C3-/- mice behaved similarly 
(Fig. 1.4).  Both groups began losing weight within 24 hours of infection, and rapidly 
began exhibiting clinical signs of ascending encephalomyelitis.  Peak weight loss 
and disease scores were observed at days 7-8 in both groups, and were followed by 
protracted recovery.  In both the kinetics of disease onset and recovery, as well as 
magnitude of peak weight loss and disease score, C57BL/6 and C3-/- mice were 
indistinguishable, indicating that once V3533 has entered the CNS, the host 
complement system no longer plays a significant role in influencing disease 
outcome.  
 
Complement is required for maximum anti-VEEV neutralizing activity of 
normal serum 
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One possible explanation for the defect in serum clearance and more rapid spread 
to the CNS that was observed in the C3-/- mice is that the anti-VEEV antibody 
response was diminished in the absence of complement.  During an acute, 
cytopathic viral infection, the induction of a virus-specific antibody response occurs 
2-4 days post-infection (20).  During V3533 infection, significant differences in viral 
titers in the serum and CNS between C57BL/6 and C3-/- mice were apparent by 24 
hours post-infection, suggesting that complement was acting prior to anti-VEEV 
antibody induction.  This led us to examine the effect of complement on the anti-
VEEV activity of natural antibody.  Serum was collected from uninfected C57BL/6, 
C3-/-, or B cell-deficient µMT mice, left untreated or heated to 56˚C for one hour to 
inactivate complement, and then assayed for in vitro anti-VEEV neutralizing activity 
on BHK-21 cells. 
 
Normal serum from C57BL/6 mice exhibited a surprising amount of anti-VEEV 
neutralizing activity (Fig. 1.5).  Wild-type serum at a concentration of only 2.5% was 
sufficient to neutralize nearly 70% of VEEV infectivity, with an IC50 of 1:49.  In the 
absence of functional complement, either due to heat inactivation or genetic 
deficiency in C3, neutralizing activity was reduced ~45-50%, demonstrating that the 
anti-VEEV neutralizing activity of normal serum was partially complement-
dependent.  
 
Anti-VEEV antibody responses are intact in C3-/- mice 
  93 
Complement activation is a requirement for the induction of anti-viral antibody 
responses following infection with several different viruses.  While the similar results 
following i.c. infection of C57BL/6 and C3-/- mice suggested that the protective effect 
of complement was not related to antibody induction, we wanted to directly confirm 
this.  C57BL/6 and C3-/- mice were infected sub-cutaneously in the footpad with 106 
pfu of V3533, and serum was collected at days 2, 4, 8, and 12 post-infection to 
assay anti-VEEV binding and neutralization activity.   
 
In both C57BL/6 and C3-/- mice, VEEV-specific IgM was induced between days 2 
and 4 post-infection, while VEEV-specific IgG appeared between days 4 and 8 post-
infection (Fig. 1.6A).  At all time points examined, VEEV-specific IgM titers were 
similar between C57BL/6 and C3-/- mice, with the exception of day 12 post-infection 
where titers were higher in the C3-/- mice.  IgG induction in C3-/- mice appeared to be 
slightly delayed, as titers were slightly lower at day 8, compared with C57BL/6.  
While this difference was statistically significant (p=0.0159, Mann Whitney), titers in 
both groups were quite high.  By day 12, IgG levels in both groups were equivalent.  
In addition to ELISA, which measures the amount of anti-VEEV antibody but not its 
biological activity, we assessed the anti-VEEV neutralizing activity of serum 
collected at day 4 post-infection, the timepoint when viral burdens within the CNS 
were most divergent (Fig. 1.6B).  Similar to the ELISA results, no difference was 
seen in neutralizing activity between C57BL/6 and C3-/-.  Together, these results 
demonstrated that complement was not required for the development of an anti-
VEEV antibody response. 
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Recruitment of inflammatory cells to early sites of V3533 replication is similar 
between wild-type and C3-/- mice 
Complement activation can play a role in the recruitment and activation of 
inflammatory cells to sites of infection. It was possible that the sustained viremia 
observed in the C3-/- mice resulted from an inability to restrict the production of virus 
at early sites of replication, rather than a defect in removing virus from circulation.  
Thus regulation of the inflammatory response at early sites of replication might 
influence the duration of viremia.  To assess whether the absence of complement 
affected the recruitment of inflammatory cells to early sites of viral replication, we 
examined the draining popliteal lymph node at 48 hours post-infection as a 
representative early site of VEEV replication.  Single cell suspensions were 
generated from the lymph nodes, and inflammatory cells were identified based on 
their surface staining profile. 
 
As would be expected, B and T lymphocytes were by far the most numerous cell 
populations present, and were found in similar numbers in both groups (data not 
shown).  Looking at cell populations more associated with an inflammatory 
response, we observed no major differences in the numbers of NK cells (CD3-, 
CD49b+), NKT cells (CD3+, CD49b+), neutrophils (Ly6G+, CD11b+, MHC class II-), 
macrophages (CD11b+, CD11c-, MHC class II+), or conventional dendritic cells 
(CD11c+, B220-) between C57BL/6 and C3-/- mice (Fig. 1.7A).  We did observe 
~50% fewer plasmacytoid dendritic cells (CD11c+, B220+) in the C3-/- mice, though 
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our group sizes were too small to determine whether the difference was significant.  
As the primary function of plasmacytoid dendritic cells during viral infection is 
thought to be the production of type I IFN, we used a bioassay to compare the 
amount of IFN present in the draining lymph nodes of C57BL/6 and C3-/- mice at 24 
hours post-infection, the first time point at which serum titers were divergent.  Using 
this approach, we saw no difference in the amount of IFN present in the draining 
lymph nodes at 24 hours post-infection, suggesting that there was no significant 
difference in plasmacytoid dendritic cell activity between the two groups (Fig. 1.7B).      
 
DISCUSSION 
The complement system has been reported to play a key protective role in the host 
response to a number of viral pathogens, though the specific mechanisms involved 
differ between viruses.  For many viruses, including West Nile virus, influenza A 
virus, and vesicular stomatitis virus, complement acts by enhancing B and T cell 
responses, thus facilitating adaptive control of the infection and clearance (32, 41, 
45, 47).  In the cases of Sindbis virus and ectromelia virus, complement appears to 
act within the first hours of infection, limiting viral dissemination and thus 
downstream pathology (23, 45).  In this study, we assessed the role of the host 
complement system in a model of recovery from acute VEEV infection.  Together, 
our results demonstrate that the complement system plays an important role in 
limiting neuropathology following VEEV infection.  This protective effect resulted 
from complement function in the periphery during the first 24 hours of infection, and 
appeared to be independent of inflammatory cell recruitment or anti-VEEV antibody 
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induction.  While the exact mechanism responsible for this effect remains unclear, 
our results suggest that complement-mediated enhancement of natural antibody 
activity might be involved.    
 
The results of this study clearly demonstrated that complement activity in the 
periphery, but not the CNS, had a profound effect on the extent of virus-induced 
neuropathology.  In the absence of complement, clearance of VEEV from the serum 
was less efficient, and virus appeared within the CNS within 24 hours of infection, 
compared with 48 hours in the presence of complement.  The earlier arrival of VEEV 
within the CNS of C3-/- mice, compared with wild-type mice, would allow the virus to 
replicate and spread to a greater degree prior to the generation of VEEV-specific B 
and T cell responses.  A larger viral burden would most likely trigger a more robust T 
cell response within the CNS, potentially resulting in more severe immune-
pathology.  While we feel that this is a likely explanation for the more severe 
encephalomyelitis and neuropathogy observed in C3-/- mice relative to C57BL/6, 
more work is clearly needed to examine the relationship between complement, viral 
spread within the CNS, and the magnitude of the T cell response. 
 
VEEV invasion of the CNS is thought to occur via diffusion of virus from the blood 
through fenestrated capillary endothelial tight junctions to nearby peripheral nerve 
endings, followed by centripetal spread to the brain (9).  One consequence of this 
route of neuroinvasion is that the efficiency of invasion is a direct function of 
infectious virus concentration within the serum.  This hypothesis is supported by the 
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observation that there was a minimum virus concentration in the serum of VEEV 
infected mice (≥104 pfu/mL) that was required for invasion of the brain (Bernard K., 
unpublished results).  Thus any host function that limits either the magnitude or 
duration of serum viremia would also reduce the efficiency of neuroinvasion.  While 
this connection has not been directly tested, a number of studies, with VEEV as well 
as Sindbis virus and western and eastern equine encephalitis viruses, have 
correlated the duration of serum viremia with virulence (5, 25-27, 36).              
 
In C57BL/6 mice, viral titers in the serum were significantly reduced from their peak 
by 24 hours post-infection, and were nearly absent by 48 hours post-infection, prior 
to the development of a VEEV-specific antibody response.  Thus, it appears likely 
that natural antibodies play a significant role in clearing VEEV from circulation.  One 
possible explanation for the delay in serum clearance observed in the C3-/- mice is 
that complement is required for the maximal anti-viral activity of natural antibodies.  
Natural antibodies are produced constitutively, independently of internal or external 
stimuli, and have a fairly wide range of binding avidities, depending on the antigen 
and host genetic background (48).  Despite being produced in a non-specific 
manner, the anti-viral neutralizing activity of natural antibodies can be high, ranging 
from titers of 1:8 to 1:32 for vesicular stomatitis virus between different mouse 
strains (16).  When we examined the anti-VEEV neutralizing activity of normal 
serum, we found that it was quite high, with an IC50 of about 1:50.  This could 
potentially explain why serum clearance occurs so rapidly in wild-type mice.  In the 
absence of complement, the neutralizing activity of normal serum was reduced 
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substantially, indicating that much of its activity was complement-dependent.  
Surprisingly, heat-inactivated µMT serum retained a significant amount of 
neutralizing activity, despite lacking both antibody and functional complement.  Heat 
inactivation at 56˚C prevents the subsequent activation of the complement system, 
but it is possible that some complement components, the collectins for instance, may 
retain the ability to bind viral particles and hinder attachment or entry.  Alternatively, 
serum may contain elements in addition to antibody and complement that exert 
some anti-VEEV neutralizing activity.    
 
While these results suggest a role for complement in enhancing the anti-VEEV 
neutralizing activity of normal serum, further studies are needed to pinpoint the exact 
mechanism.  The C1q protein has been shown to enhance antibody-mediated 
neutralization of West Nile virus by reducing the number of bound antibody 
molecules required to neutralize a single particle (40).  We feel that is it unlikely that 
a similar C1q-dependent mechanism is contributing to the effect that we observed 
with VEEV for two reasons.  First, the effect of C1q on West Nile virus neutralization 
was purely a function of soluble C1q protein, independent of complement activation 
or C3, whereas natural antibody-mediated neutralization of VEEV is C3 dependent.  
Second, infection of C1q-/- mice with V3533 did not result in the development of the 
overt encephalomyelitis that was observed in C3-/- mice, suggesting that C1q was 
not required for the protective effect of complement activation in our system (data 
not shown).  Studies with ectromelia virus using normal sera from a panel of mice 
with deficiencies in various complement components demonstrated that both the 
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classical and alternative pathways of complement activation were required for 
maximal in vitro neutralization (45).  Based on the absence of neutralization in the 
absence of C3 or C4, Moulton et al. concluded that neutralization was primarily the 
result of opsonization of viral particles by C3b and C4b.  A slight reduction in 
neutralizing activity in the absence of C5 suggested an additional role for the 
membrane attack complex.  Further work is underway to assess the relative 
contributions of the opsonins and the membrane attack complex to VEEV 
neutralization.          
 
In addition to enhancing natural antibody-mediated neutralization of circulating virus 
particles, complement activation might be facilitating serum clearance of VEEV by 
antibody-independent mechanisms.  Seven distinct complement receptors (CR1, 
CR2, CR3, CR4, SIGN-R1, CRIg, and C1qR) have been identified as binding and 
facilitating clearance of complement-bound pathogens from circulation (14, 21, 24, 
28-30).  These receptors are expressed by phagocytic cells such as marginal zone 
macrophages in the spleen and Kupffer cells in the liver, and could potentially act to 
eliminate complement-bound VEEV particles from the serum.  This mechanism 
could potentially explain the higher viral burdens observed in the spleens of wild-
type mice over the first 24 hours of infection, compared with C3-/- mice.  Further 
evaluation of serum clearance in mice lacking the various complement receptors is 
needed to assess the importance of this mechanism in controlling early VEEV 
infection.   
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The finding that anti-VEEV IgM and IgG responses were intact in the absence of 
complement was surprising given the complement-dependence of antibody 
responses to a variety of other viral infections.  Complement activation can enhance 
virus-specific antibody induction through multiple mechanisms.  Recognition of 
complement-coated antigen by CR1 and/or CR2 expressed on B cells can lower the 
signaling threshold required for activation, while CR1 and CR2 expressed by 
follicular dendritic cells can act to retain complement-coated antigen within B cell 
follicles, enhancing presentation to B cells (3, 7).  CR1 and CR2 have been 
demonstrated to be essential for the humoral response to both West Nile virus and 
herpes simplex virus, though it is not known which CR1/CR2 functions are involved 
(41, 54).  It is possible that the replication of VEEV to such high titers (106-107 
pfu/draining popliteal lymph node) in secondary lymphoid organs may provide 
enough concentrated viral antigen and inflammatory stimulus to render CR1/CR2 
function unnecessary.   Type I interferon, which is produced in large amounts during 
VEEV infection, can also act directly on B cells to promote antibody production and 
may thus compensate for the lack of CR1/CR2 signaling in C3-/- mice (10, 13, 60). 
 
Complement activation can play a major role in the recruitment and activation of NK 
cells, neutrophils, monocytes/macrophages, dendritic cells, and other inflammatory 
cell populations.  Thus, we felt that it was possible that at least some component of 
the early inflammatory cell response to VEEV would be complement dependent (19, 
34, 38, 42, 46, 52, 55).  While more thorough analysis is still needed, it appeared 
that inflammatory cell recruitment was comparable between V3533-infected wild-
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type and C3-/- mice.   This mirrors what has been described in mice infected with the 
arthritogenic alphavirus Ross River virus, where inflammatory cell recruitment was 
independent of complement activation (43, 44).  The robust recruitment of 
inflammatory cells in the absence of complement activation might be explained by 
the robust inflammatory cytokine and chemokine response that is induced early 
during VEEV infection (31).  Further work is still needed to rule out a role for 
complement activation in regulating the activation status and/or antiviral 
effectiveness of these inflammatory cell populations following recruitment to sites of 
infection. 
 
Together, the results described here demonstrate that interactions between VEEV 
and the host complement system during the first hours of peripheral infection can 
have profound effects on downstream disease outcome.  Furthermore, they suggest 
important roles for natural antibody and complement activation in limiting VEEV 
invasion of the CNS.       
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Figure 2.1 
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Figure 2.1:  Complement activation limits disease severity following V3533 
infection.  6-10 week old C57BL/6J or C3-/- mice (7-8 mice per group) were infected 
with 106 PFU of V3533 in the left rear footpad.  (A) Weight loss and (B) disease 
score following infection.  Mice were scored according to the following scale: 0 – no 
signs; 1 – hunched posture, ruffled fur; 2 – mild motor dysfunction, altered gait; 3 – 
moderate motor dysfunction, ataxia; 4 – severe motor dysfunction, hind limb 
paresis/paralysis; 5 – moribund.  Each data point represents the arithmetic mean ± 
standard error of the mean (SEM).  These results are representative of 3 
independent experiments.  *, P < 0.05; **, P < 0.01 by Mann-Whitney testing.   
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Figure 2.2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2:  V3533-induced brain inflammation in C57BL/6 and C3-/- mice. 6-10 
week old C57BL/6J or C3-/- mice were injected with either 106 PFU of V3533 or 
diluent alone in the left rear footpad.  At day 6 post-infection, mice were sacrificed 
and perfused with 4% paraformaldehyde.  5 µM sections paraffin-embedded sagittal 
sections were generated and stained with H&E.  Sections are representative of 2 
mice per group. 
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Figure 2.3 
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Figure 2.3:  V3533 tissue titers in C57BL/6 and C3-/- mice. 6-10 week old 
C57BL/6J or C3-/- mice were infected with 106 PFU of V3533 in the left rear footpad.  
At the indicated times post-infection (Day P.I.), serum, spleen, draining popliteal 
lymph node, brain, and spinal cord were collected and homogenized.  Viral burden in 
each tissue was determined by standard plaque assay on BHK-21 cells.  Data points 
represent individual titers pooled from three independent experiments, and bars 
indicate the geometric mean.  *, P < 0.05; **, P < 0.01 by Mann-Whitney testing.    
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Figure 2.4 
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Figure 2.4:  Disease outcome following intracranial inoculation of V3533. 6-10 
week old C57BL/6J or C3-/- mice (8 mice per group) were infected intracranially with 
103 PFU of V3533.  (A) Weight loss and (B) disease score following infection.  Mice 
were scored according to the following scale: 0 – no signs; 1 – hunched posture, 
ruffled fur; 2 – mild motor dysfunction, altered gait; 3 – moderate motor dysfunction, 
ataxia; 4 – severe motor dysfunction, hind limb paresis/paralysis; 5 – moribund.  
Each data point represents the arithmetic mean ± standard error of the mean (SEM).  
No statistically significant differences between C57BL/6J and C3-/- mice were 
detected at any time by Mann-Whitney testing.
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Figure 2.5 
  
 
Figure 2.5:  Anti-VEEV neutralizing activity of normal serum is partially 
dependent on complement activation.  Anti-VEEV neutralizing activity of normal 
serum from C57BL/6J, µMT, and C3-/- mice, untreated or heat-inactivated for 1 hour 
at 56°C, was assessed in vitro on BHK-21 cells.  Data represents the percentage of 
viral infectivity lost following 1 hour incubation with the indicated serum at a final 
concentration of 2.5%, compared with virus incubated in the absence of serum.  
Each bar represents the arithmetic mean of two replicates.    
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Figure 2.6 
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Figure 2.6:  Anti-VEEV antibody response is intact in C3-/- mice. 6-10 week old 
C57BL/6J or C3-/- mice were infected with 106 PFU of V3533 in the left rear footpad.  
(A) At the indicated times post-infection (Day P.I.), mice were bled, and the amount 
of VEEV-specific IgM and IgG was determined by anti-VEEV ELISA.  Data is 
presented as the log10 reciprocal dilution at which 50% of the maximal absorbance 
value was reached.  Individual data point represent single animals, and are pooled 
from two independent experiments.  (B) The anti-VEEV neutralizing activity of serum 
collected from C57BL/6J and C3-/- mice at day 4 post-infection.  Data is presented as 
the log10 reciprocal dilution at which 50% of infectivity was inhibited, and horizontal 
bars represent the arithmetic means of 3-5 animals per group. *, P < 0.05 by Mann-
Whitney testing. 
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Figure 2.7 
 
 
 
Figure 2.7:  Inflammatory cell recruitment to early sites of V3533 replication is 
complement-independent. 6-10 week old C57BL/6J or C3-/- mice were infected 
with 106 PFU of V3533 in the left rear footpad. (A) At day 2 post-infection, mice were 
perfused with PBS and single cell suspensions were generated from the draining 
popliteal lymph node, stained for various surface markers, and analyzed by flow 
cytometry.  Total numbers of NK cells (CD3-/CD49b+), NKT cells (CD3+/CD449b+), 
granulocytes (Ly6G+/CD11b+/MHC class II-), plasmacytoid dendritic cells (pDC) 
(CD11c+/B220+), and conventional dendritic cells (cDC) (CD11c+/B220-) isolated 
from lymph nodes.  Bars represent the arithmetic mean ± SEM of 2 mice per group.  
(B) At 24 hours post-infection, mice were perfused with PBS and draining popliteal 
lymph nodes were isolated and homogenized.  Amounts of type I IFN were 
determined by bioassay.  Bars represent the arithmetic mean of results form 3-4 
mice per group.  Results were statistically indistinguishable by Mann-Whitney 
testing.
  
 
 
 
 
CHAPTER 3: 
T CELLS FACILITATE RECOVERY FROM VENEZUELAN EQUINE 
ENCEPHALITIS VIRUS-INDUCED ENCEPHALOMYELITIS IN THE ABSENCE OF 
ANTIBODY 
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Abstract 
Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne RNA virus of the 
genus Alphavirus that is responsible for a significant disease burden in Central and 
South America through sporadic outbreaks into human and equid populations.  In 
humans, 2-4% of cases are associated with encephalitis, and there is an overall 
case mortality rate of approximately 1%.  In mice, replication of the virus within 
neurons of the central nervous system (CNS) leads to a paralyzing, invariably lethal 
encephalomyelitis.  However, mice infected with certain attenuated mutants of the 
virus are able to control the infection within the CNS and recover.  To better define 
what role T cells responses might be playing in this process, we infected B cell-
deficient µMT mice with a VEEV mutant that induces a mild, sub-lethal illness in 
immune competent mice.   Infected µMT mice rapidly developed the clinical signs of 
severe paralyzing encephalomyelitis, but were eventually able to control the infection 
and recover fully from clinical illness.  Recovery in this system was T cell-dependent, 
and associated with a dramatic reduction in viral titers within the CNS, followed by 
viral persistence in the brain.  Further comparison of the relative roles of T cell 
subpopulations within this system revealed that CD4+ T cells were better producers 
of IFNγ expression and were more effective at controlling VEEV within the CNS, 
compared with CD8+ T cells.  Overall, these studies suggest that T cells, especially 
CD4+ T cells, can successfully control VEEV infection within the CNS and facilitate 
recovery from a severe viral encephalomyelitis.
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INTRODUCTION 
Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne RNA virus of the 
genus Alphavirus that is responsible for a significant disease burden in Central and 
South America through sporadic outbreaks into human and equid populations (20, 
57).  The most recent major outbreak occurred in 1995 with 75,000 to 100,000 
human cases spread between Columbia and Venezuela (59).  In humans, only 1-2% 
of cases progress to full-blown encephalitis, though roughly 50% of those cases are 
fatal (58).  In equid populations, however, the mortality rate is much higher, often 
over 50% (56).  Because of the high probability of future natural outbreaks, as well 
as its potential use as a bioterrorism agent, VEEV remains a significant public health 
concern (43).  Currently, there are no therapeutics or licensed vaccines available for 
human use.    
 
Work with multiple infection models has shown that both the innate and adaptive 
arms of the host immune response are involved in successful control of viruses that 
target CNS neurons (21).  Disruption of the type I interferon system dramatically 
decreases the average survival time of mice infected with VEEV, as well as Sindbis 
and West Nile viruses (45, 46, 60).  Studies with a variety of neuronotropic viruses, 
including Sindbis and West Nile, have clearly demonstrated that the development of 
a virus-specific antibody response is a critical step in both limiting viral spread and 
facilitating non-cytolytic clearance of infectious virus from neurons within the brain 
(14, 32).  αβ-T cell responses also help limit lethality in many of these models by 
directly killing infected cells, producing antiviral cytokines, and/or by enhancing the 
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production and quality of virus-specific antibody (4, 38, 52, 54).  In the case of 
Sindbis virus, the T cell compartment was able to dramatically restrict viral 
replication in the CNS in the absence of anti-viral antibodies, partially through an 
interferon-γ-dependent mechanism (5).  While numerous components of the host 
immune system play a role in mediating protection or recovery from neuronotropic 
virus infection, the specific mechanisms by which the host is able to eliminate virus 
from CNS neurons, while leaving these critical, irreplaceable cells intact, remain 
unknown.  
 
Our current understanding of VEEV pathogenesis comes primarily from work in a 
well-established mouse model of infection and disease that closely mirrors many 
aspects of disease in humans and horses (18).  Following peripheral inoculation into 
the footpad of a mouse, a delivery method that mimics the natural route of infection 
by mosquito bite, the virus initiates a biphasic course of infection in which initial 
replication within the skin-draining lymph node as well as other secondary lymphoid 
tissue seeds a high-titer serum viremia (35).  The viremia facilitates virus invasion of 
the CNS, initially through non-myelinated olfactory neurons within the nasal neuro-
epithelium (11, 35).  This leads to a second phase of infection characterized by rapid 
replication and spread though CNS neurons and the eventual development of 
paralyzing encephalitis (10, 19).  Infection of inbred mice with most strains of VEEV 
results in 100% mortality (56).  Due to the extreme lethality of the virus, efforts to 
understand the host mechanisms involved in mediating recovery from VEEV-
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induced encephalomyelitis have been hampered by the lack of a relevant model 
system in which such a recovery could be reliably observed.   
 
Using a fixed cDNA clone (pVR3000) of the Trinidad Donkey strain of VEEV as a 
starting point, our lab has generated a panel of genetically defined VEEV mutants 
that are attenuated in vivo, compared to virus derived from the parental pVR3000 
clone (1, 3, 12, 19, 60).  The use of these mutants, which are attenuated at various 
definable stages of in vivo infection, has facilitated the dissection of the sequence of 
host-virus interactions that give rise to pathogenesis and/or immunity during VEEV 
infection (1, 3, 35).  One of these lab-generated mutants, labeled V3533, differs from 
the parental V3000 virus at only two residues, both within the E2 glycoprotein (E76K, 
K116E), yet these changes are sufficient to convert an invariably lethal virus into one 
that is non-lethal in immune-competent C57BL/6 mice (1).  Sub-cutaneous infection 
of C57BL/6 mice with V3533 resulted in neuroinvasion followed by rapid clearance.  
This reduction in pathogenicity did not result from an alteration of CNS cellular 
tropism, as both V3000 and V3533 exclusively infected neurons within the brain 
(Data not shown).  Thus, infection with V3533 provided a model system to study 
successful control of VEEV infection within the CNS.  
 
In order to identify the components of a successful immune response to VEEV 
infection within the CNS, we infected a number of immunodeficient mouse strains 
with V3533 and assessed disease outcome.  Infection of Rag1-/- mice with V3533 
resulted in near total lethality while infection of B cell-deficient µMT mice resulted in 
  127 
near total recovery, demonstrating that recovery from V3533 was dependent upon 
an adaptive immune response and that while antibody production contributed to 
recovery, it was not required.  Further studies demonstrated that both CD4+ and 
CD8+ T cells had direct anti-viral effects within the CNS, but that both were required 
for maximal control of V3533 infection.  
 
Materials and Methods 
Viruses 
The isolation of wild-type V3000 and the V3533 mutant of VEEV, as well as the 
generation of the pVR3000 and pVR3533 molecular clones have been described 
previously (1, 13).  Virus stocks of V3533 were generated by in vitro transcription 
from a linearized plasmid, pVR3533, which encodes the full-length V3533 cDNA, 
using a T7-specific mMessage mMachine in vitro transcription kit (Ambion).  In vitro-
generated transcripts were then electroporated into BHK-21 cells using a Bio-Rad 
electroporator as described previously (1).  Culture supernatants were harvested 18 
hours after electroporation, clarified by centrifugation at 3000 rpm for 20 min, and 
stored as single use aliquots at -80° C.  Viral titers were determined by standard 
plaque assay on BHK-21 cells, as previously described (53). 
Mouse studies 
Rag1-/- and µMT mice (both on the C57BL/6 background) were obtained from The 
Jackson Laboratory (Bar Harbor, ME) and bred in house under specific pathogen-
free conditions.  C57BL/6 mice were purchased from The Jackson Labs as needed.  
All experimental manipulation of mice was performed in a biosafety level 3 animal 
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facility following a 7 day acclimatization period.  For infections, 6-10 week old female 
mice were anesthetized via intra-peritoneal (i.p.) injection with a mixture of ketamine 
(50 mg/Kg body weight) and xylazine (15 mg/Kg body weight) and then inoculated in 
the left rear footpad with 103 PFU of virus in diluent [phosphate buffered saline 
(PBS) + 1% donor calf serum, Ca2+, Mg2+].  Mock-infected mice received diluent 
alone.  Weight loss and disease score were assessed daily in infected animals.  The 
scale used for disease scoring was as follows: (0) no signs; (1) hunching; (2) ruffled 
fur; (3) ataxia, imbalance; (4) conjunctivitis; (5) paralysis of one or both hind limbs; 
(6) moribund.  This scale was based on the temporal order of ascending symptoms 
in µMT mice following V3533 infection.  Mice that lost more than 20% (following 
V3000 infection) or 35% (following V3533 infection) of their starting weight or 
became moribund were euthanized according to UNC Institutional Animal Care and 
Use Committee guidelines.  
Virus titers 
To assess VEEV titers in vivo, infected mice were sacrificed, bled, and then 
perfused through the heart with 10 mL of PBS.  Spleen, draining popliteal lymph 
node, brain and spinal cord were then removed, weighed, and frozen at -80°C in 
diluent.  Tissues were then thawed, homogenized, and used to infect BHK-21 cells 
in a standard plaque assay.  
In vivo depletions  
µMT mice received i.p. injections of 0.5 mg of depletion antibody in 0.1 mL of PBS 
24 hours prior to V3533 infection, 24 hours following infection, and every 72 hours 
subsequently until the termination of the experiment at day 25 post-infection.  
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Depleting antibodies used were 17A2 (αCD3), GK1.5 (αCD4), 2.43 (αCD8), and 
LTF2 (isotype control) (all Bio X Cell).  At day 25 post-infection, mice were bled and 
then sacrificed by exsanguination.  Brains and spinal cords were collected for titering 
as described above, and spleens were collected to assess depletion efficacy by flow 
cytometry. 
Quantification of CNS leukocytes and flow cytometry 
Mock and V3533-infected mice were sacrificed by exsanguination and perfused with 
PBS.  Brains and spinal cords were harvested, minced, and then incubated for 1.5 
hours with vigorous shaking at 37°C in digestion media [RPMI, 1% fetal calf serum, 
25mM HEPES, 1.25 mg/mL Collagenase A (Roche)].  Homogenates were then 
passed through a 40 µm strainer and pelleted through 25% Percoll (GE Healthcare) 
in media (RPMI, 1% fetal celf serum, 25mM HEPES) for 20 min at 800g.  Resulting 
pellets were then resuspended in 30% percoll, overlayed above 70% Percoll, and 
centrifuged for 20 min at 800g.  The interface was collected and washed with media, 
and the absolute number of live cells in each sample was then determined by trypan 
blue exclusion.  Cells were washed in flow cytometry wash buffer (1 x Hank’s 
balanced salt solution, 1% fetal calf serum, 0.1% sodium azide) and then stained 
with the following antibodies: anti-CD45-biotin coupled with streptavidin-conjugated 
PerCP, anti-CD11b-PE-Cy7, anti-MHC Class II-APC, anti-Ly6G-FITC (clone 1A8), 
anti-CD3ε-PE (all eBioscience); anti-CD4-Pacific Blue, and anti-CD8-Pacific Orange 
(both Caltag).  All staining was done in the presence of anti-mouse FcγRII/III (clone 
2.4G2; BD Pharmingen) to prevent non-specific antibody binding.  Following 
staining, samples were fixed in 2% paraformaldehyde in PBS and analyzed on a 
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CyAn flow cytometer using Summit 5.2 software (Dako).  Absolute numbers of each 
specific cell type were calculated by determining the number of total live cells within 
a sample by trypan blue exclusion and then multiplying that number by the 
percentage of live cells within the sample bearing the appropriate surface staining 
profile.  
Ex vivo analysis of CNS leukocytes 
Leukocytes were isolated as described above.  For samples receiving no ex vivo 
stimulus, cells were cultured in T cell culture media (RPMI + 10% fetal calf serum, 50 
µM β-mercaptoethanol) with 3 µg/mL brefeldin A (eBioscience) for 4 hours at 37° C.  
For samples receiving stimulus, cells were cultured in T cell culture media with 50 
ng/mL PMA and 500 ng/mL ionomycin for 6 hours at 37° C, with brefeldin A added 
for the last 4 hours. CD107a staining was performed during brefeldin A treatment, in 
the presence of 2 µM monensin and 1:100 anti-CD107a-AF488 or isotype control 
(eBioscience).  Cells were then washed in flow cytometry wash buffer and stained 
with the following antibodies: anti-CD69-PE-Cy5, anti-CD3ε-PE (both eBioscience); 
anti-CD4-Pacific Blue, and anti-CD8-Pacific Orange (both Caltag).  Following 
surface staining, cells were washed twice and then simultaneously fixed and 
permeabilized in Cytofix/Cytoperm (BD Biosciences) for 30 min.  Permeabilized 
samples were stained for intracellular expression using the following antibodies: anti-
Ki-67-FITC, anti-IFNγ-PE-Cy7, anti-TNFα-FITC, anti-IL-2-APC, anti-IL-10-APC, anti-
IL-17-APC, or the appropriate isotype controls (all eBioscience).  All staining was 
done in the presence of anti-mouse FcγRII/III (2.4G2; BD Pharmingen) to prevent 
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non-specific antibody binding.  Samples were then washed twice in 
Cytoperm/Cytowash (BD Biosciences) and then analyzed on a CyAn flow cytometer.    
 
RESULTS 
V3533 provides a relevant model of viral clearance and recovery 
Following sub-cutaneous, footpad injection of C57Bl/6 mice with 106 pfu of V3533, 
the early stages of viral replication and spread were similar to those observed 
previously with the more virulent parental virus, V3000 (Fig 1A, data not shown) 
(19).  Virus was first observed in the draining popliteal lymph node, spleen, and 
serum by 24 hours post-infection.  The virus first became detectable in the brain by 
plaque assay at day 2 post-infection, while titers in secondary lymphoid organs and 
serum were reduced considerably by this timepoint.  Viral titers peaked within the 
CNS around day 4, but unlike wild-type virus that maintained high titers within the 
CNS until the inevitable death of the host (data not shown), titers of V3533 began to 
decline by day 6, and by day 8, infectious virus was no longer detectable by plaque 
assay.  Replication of V3533 within the CNS was associated with a small, but 
significant loss of weight relative to mock in multiple independent experiments (Figs 
1B, 2).  Upon clearance, infected mice began regaining weight and eventually 
stopped exhibiting outward signs of disease.  Thus, V3533 provides a model of 
VEEV infection in which the host is able to successfully clear the virus from the CNS 
and recover from clinical illness.     
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Antibody production is not required for recovery from V3533-induced 
encephalomyelitis 
The role of the adaptive component of the immune system in mediating protection or 
recovery during VEEV infection has been tested primarily in the context of 
vaccinated animals, or animals receiving passive transfer of immune sera.  While 
these studies have been instructive, we were interested in what role the adaptive 
response could play during the infection of a naïve animal.  To answer this question, 
we determined whether the observed control of V3533 by C57Bl/6 mice was 
dependent on the adaptive arm of the immune system.   
 
Rag1-/- mice, which lack functional B and T cells, as well as µMT mice, which lack 
functional B cells, were infected with 103 pfu of V3533 sub-cutaneously in the 
footpad.  Rag1-/- mice initially behaved similarly to wild-type mice, losing little or no 
weight, and showing no outward signs of disease for the first 4 days post-infection 
(Fig 2).  At day 4, infected Rag1-/- mice began losing weight, and by day 8 post-
infection had lost roughly 20% of their starting weight.  They also developed clinical 
signs of disease including hunched posture, ruffled fur, ataxia, and a marked 
reduction in cage exploration.  Weight loss and clinical signs of disease in infected 
Rag1-/- mice progressed rapidly between days 4 and 8 post-infection, but the clinical 
condition of the animals then stabilized, and over the next 10 days both weight and 
clinical score remained virtually unchanged.  Starting around day 18 post-infection 
however, infected Rag1-/- mice suffered further weight loss, culminating in death.  
V3533 infection of Rag1-/- mice resulted in 93% lethality (n=15) over 40 days of 
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observation, with an AST of 30+/-5 days.  The difference in disease outcome 
observed between C57BL/6 and Rag1-/- mice clearly demonstrated that successful 
control of V3533 infection is dependent upon an intact adaptive immune response.   
 
The importance of an intact antibody response was demonstrated by following 
V3533 infection of µMT mice.  Between days 4 and 9 post-infection, µMT mice lost 
about 30% of their starting weight and developed the outward signs of severe 
encephalomyelitis, including convulsions, conjunctivitis, and hind-limb paresis or 
paralysis.  This dramatically enhanced pathology, compared with the much milder 
disease observed in wild-type mice, illustrated the critical role that antibody 
production played in mounting a successful response to VEEV infection.  
Surprisingly, despite the extremely severe morbidity observed, the vast majority of 
these animals (92.7%, 64/69) went on to recover.  Recovery of µMT mice was 
somewhat protracted, with mice not regaining their full starting weights until weeks 
later.  Most outward signs of encephalomyelitis or febrile illness disappeared in 
recovered µMT mice, though these animals retained a slight tentativeness in their 
movements that was still observable 15 weeks after infection.  The stark contrast in 
disease outcome following V3533 infection in µMT mice versus Rag1-/- mice clearly 
demonstrated that other adaptive mechanisms in addition to antibody production 
could play a major protective role during VEEV infection. 
   
Recovery in µMT mice is associated with dramatic reduction of viral titers in 
the brain and clearance of infectious virus in the spinal cord  
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Persistent CNS infection by wild-type VEEV in mice has not been reported.  The 
unexpected recovery observed in V3533-infected µMT mice lead us to ask whether 
the observed recovery was associated with clearance of virus from the CNS or the 
establishment of viral persistence.  To answer this question, we infected µMT mice 
sub-cutaneously in the footpad with 103 pfu of V3533, and then sacrificed animals at 
various times post-infection and assessed viral burden in relevant tissues by plaque 
assay.   
 
The pattern of early V3533 replication and dissemination observed in µMT mice 
differed somewhat from the classic biphasic course of infection that has previously 
been seen in VEEV-infected immune-competent mice (1).  Virus was first seen in the 
draining popliteal lymph node within 12 hours of inoculation, and the spleen and 
serum by 24 hours.  Rather than being rapidly cleared from these compartments, as 
it is in C57BL/6 mice, infectious V3533 remained detectable in both serum and 
spleen for weeks following inoculation (Fig 3A).  Of 6 mice examined at 15 weeks 
post-infection, virus was still detectable in serum (4/6) and spleen (2/6) by plaque 
assay (Fig 3B).   
 
V3533 first appeared in the brains of µMT mice around 24 hours post-infection, and 
rapidly reached peak titers of around 106 pfu/gram by day 4.  The appearance of 
virus in the spinal cord was slightly delayed, with infectious virus first detectable at 
48 hours post-infection and peak titers being reached at day 6 (Fig 3A).  Thus, the 
kinetics of neuroinvasion and initial replication of the virus within the CNS were 
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similar to that observed in C57BL/6 mice.  Between days 6 and 8 however, titers in 
both brain and spinal cord began to fall, and by day 15 post-infection had been 
reduced to within a log of the limit of detection.  Following this initial reduction of viral 
titers within the CNS, infectious virus was cleared from the spinal cord between days 
15 and 30 post-infection, but continued to persist in the brains of the majority of 
animals tested through week 15 (day 105), indicating the development of a chronic 
infection (Fig 3B).  This divergence in the ability of the brain and spinal cord to clear 
virus in the absence of antibody mirrors what has been reported previously with 
Sindbis virus in these mice (5).   
 
Given that µMT mice were able to control V3533 infection within the CNS and 
recover from infection, we next asked whether the mortality observed in V3533-
infected Rag1-/- mice was due to an inability to control viral replication.  To answer 
this question, we directly compared both systemic and CNS titers between µMT and 
Rag1-/- mice at days 6 and 25 following sub-cutaneous infection with 103 pfu of 
V3533.  While viral titers were high at day 6 post-infection in both µMT and Rag1-/- 
mice, by day 25 µMT mice were able to reduce titers in both serum and brain 
substantially, while Rag1-/- mice continued to maintain extremely high titers in both 
tissues, potentially explaining the enhanced mortality rate in these mice (Fig 3C). 
 
Reduction in viral CNS titers is concurrent with influx of inflammatory 
monocytes and T cells  
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The dramatic reductions in CNS titers in the absence of anti-viral antibody led us to 
ask which immune cell populations were responsible.  We first identified leukocyte 
populations present in the brains and spinal cords of V3533-infected mice over the 
course of infection.  µMT mice were infected sub-cutaneously in the footpad with 103 
pfu of V3533.  At different times post-infection, infected animals were sacrificed and 
CNS-infiltrating leukocytes were isolated.  Different leukocyte populations were then 
identified by surface phenotype and quantified by flow cytometry (Fig 4A). 
 
The vast majority of leukocytes in the uninfected CNS were identified as resting 
microglia, defined as CD11b+ CD45loMHC class IIlo, with minimal numbers of other 
populations being detectable (17, 49).  Following invasion of the CNS by V3533, 
however, this picture changed dramatically.  Between days 4 and 10 post-infection, 
a massive expansion in a CD11b+ CD45hi Ly-6G- MHC class IIhi population, defined 
as inflammatory monocytes, was observed (16, 29, 49).  This population increased 
in both number and activation state, assessed by MHC class II expression, over this 
time period (Fig 4B, data not shown) (55).  Between days 6 and 10 post-infection, 
the number of CD4+ and CD8+ T cells within the CNS increased from barely 
detectable to 106 cells/brain and 105 cells/spinal cord. After peaking at day 10, these 
inflammatory cell populations began rapidly contracting, with inflammatory 
monocytes and T cell populations exhibiting a 5-10 fold decrease in numbers by day 
15 post-infection (Fig 4B).  Interestingly, the period during which infected µMT mice 
exhibited increasing severity of disease signs and weight loss corresponded in time 
precisely with the period during which inflammatory monocytes and T cell numbers 
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within the CNS expanded, while the onset of recovery in those animals 
corresponded with the contraction of those cell populations (Fig 2). 
 
Due to the persistence of low levels of infectious virus in the brains of recovered 
µMT mice, we asked whether different inflammatory cell populations were retained in 
the CNS during the chronic phase of the infection.  Comparing total cell numbers in 
the brains of µMT mice 70 days after infection with V3533 with those from mock 
infected µMT mice, we found significantly elevated numbers of inflammatory 
monocytes, CD4+, and CD8+ T cells, but not microglia, in the infected group.  In the 
spinal cord, all cell populations tested were significantly elevated above mock (Fig 
4C; p<0.05, Mann Whitney).  Additionally, microglia and inflammatory monocytes 
from the persistently infected mice showed significantly higher levels of MHC class II 
staining relative to mock, indicating that they retained an activated phenotype 
(p=0.0286, Mann Whitney, Data not shown).  
 
T cells are required for control of V3533 infection and recovery in µMT mice  
Numerous studies demonstrating the importance of T cells in mediating anti-viral 
immunity in other viral systems, as well as the dramatic difference that we observed 
in survival rates between µMT and Rag1-/- mice, suggested that T cells are required 
for the recovery observed in V3533-infected µMT mice.  It was also possible that the 
relative contributions of CD4+ and CD8+ populations to control of the infection and 
recovery differed.  To address these questions, we treated µMT mice with depleting 
antibodies against CD3, CD4, or CD8, or with an isotype control antibody.  Weight 
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loss and disease score were observed for 25 days following infection, at which point, 
surviving mice were sacrificed and assayed for viral burden in the CNS as well as 
serum.  The efficacy of the depletion treatments also was assessed at the 
termination of the experiment by flow cytometric analysis of splenocytes (Fig 5A). 
 
In terms of disease outcome, the antibody isotype control group was 
indistinguishable from untreated µMT mice following V3533 infection, with animals 
developing the same overt signs of severe encephalomyelitis and then recovering 
(Figs 2, 5B).  The CD3-depleted group immediately began exhibiting signs of illness 
upon infection, including weight loss, hunching, ruffling, and ataxia.  These disease 
signs closely mirrored what was observed in V3533-infected Rag1-/- mice, without 
the convulsions, conjunctivitis, and hind limb paresis observed in infected µMT mice.  
Also similar to the disease observed in Rag1-/- animals, illness in the CD3-depleted 
group was prolonged but generally sub-lethal, with 3 of 4 animals still alive at the 
termination of the experiment at day 25 post-infection.  Those surviving animals 
appeared to be nearing death, however, suggesting that lethality would have been 
100% had the experiment been allowed to continue.  The one significant difference 
observed between the CD3-depleted group and Rag1-/- was that the onset of 
disease was much more rapid in the CD3-depleted group, with signs of fever and 
weight loss easily observable by 24 hours post-infection (Figs 2, 5B, data not 
shown).  This is most likely not an artifact of the depletion as both the CD4 and CD8-
depleted groups exhibited the same delay between infection and disease onset as 
untreated µMT mice. 
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In order to more directly examine the role of T cells in controlling V3533 infection in 
µMT mice, we compared viral burdens at 25 days post-infection both within the CNS 
and systemically between the different depleted groups with those in the control 
group (Fig 5C).  As expected, based on infection of untreated µMT mice, the 
antibody isotype control treated group showed low to undetectable viral burdens in 
the brain and serum, and no detectable infectious virus in the spinal cord.  The CD3-
depleted mice however, demonstrated a complete inability to control the infection, 
with titers in all three compartments tested ranging from 105 pfu/mL in the serum to 
107 pfu/g in the brain.  These results clearly demonstrated a requirement for the T 
cell compartment in controlling V3533 infection in the absence of antibody. 
 
Both CD4+ and CD8+ T cells are required for effective control of V3533 
infection in µMT mice 
Initial disease severity in both CD4 and CD8-depleted groups appeared to be 
somewhat intermediate between the control and CD3-depleted groups.  During the 
time of peak disease severity (days 9-10), both CD4 and CD8-depleted groups lost 
significantly less weight than the antibody isotype control treated group (p<0.05; 
Mann-Whitney), and neither group developed the conjunctivitis and/or hind limb 
paresis that were characteristic of V3533 infection in untreated µMT mice (Fig 5B, 
data not shown).  This indicated that both CD4+ and CD8+ T cells together were 
required for the most extreme pathology observed in µMT mice following V3533 
infection.   
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While the CD4 and CD8 depletion treatments reduced the severity of V3533-induced 
disease during the early stages of infection, they also appeared to reduce the ability 
of those animals to recover compared with the control group (Fig 5B).  At the 
termination of the experiment, 25 days post-infection, one of five CD4-depleted mice 
had already succumbed to infection, and the survivors were steadily losing weight, 
indicating that they were not successfully controlling the infection.  The CD8-
depleted group, while appearing to have recovered more fully than the CD4-depleted 
group at first, also had begun to deteriorate again by the end of the experiment, 
resulting in significantly lower weights and significantly higher disease scores 
compared with the antibody isotype control group at day 25 (both p<0.05; Mann-
Whitney).  Although the experiment was not extended long enough to determine final 
survival rates for the different groups, the status of the CD4 and CD8-depleted 
groups at the termination of the experiment strongly suggested that both CD4+ and 
CD8+ T cell populations were required for complete recovery from V3533 infection. 
 
Having established the necessity of T cells for effective control of V3533 and 
recovery, the relative contributions of the CD4+ and CD8+ compartments to the 
control of the virus both systemically and within the CNS were determined (Fig 5C).  
In the serum at day 25 post-infection, mean virus titers in both CD4 and CD8 
depleted groups were roughly three logs lower than the CD3-depleted group, though 
still elevated above the antibody isotype control group, indicating that each 
population was able to exert substantial control over systemic replication of V3533, 
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but that both populations were required for maximal control.  In the brain, mean virus 
titers in mice depleted of CD8+ cells were statistically indistinguishable from those of 
the antibody isotype control group (p=0.1761; Mann-Whitney).  Brain titers in the 
CD8-depleted group were significantly lower than in the CD3-depleted group, 
however (p=0.0357; Mann Whitney).  In the CD4-depleted group, titers were 
significantly elevated above both the control and the CD8-depleted groups 
(p=0.0294, 0.0159 respectively; Mann Whitney), but were indistinguishable from the 
CD3-depleted group (p=0.0571; Mann Whitney). In the spinal cord, we observed a 
similar trend where titers in CD8-depleted mice were significantly lower than those of 
the CD3-depleted group, but titers in CD4-depleted mice were not statistically 
distinguishable from the CD3-depleted group (p=0.4, p=0.0357 respectively; Mann 
Whitney) (Fig 5C). Together, these results suggest that within the CNS, the CD4+ 
compartment contributes the majority of the T cell-associated anti-viral activity, but 
that both CD4+ and CD8+ cells are required for maximal control. 
 
CD4+ T cells are the primary source of T cell-associated IFNγ  within the brain 
The apparent difference in antiviral activity observed between CD4+ and CD8+ cells 
within the CNS might be explained by differences in expression of cytokines or other 
indicators of effector function.  To address this possibility, we isolated T cells from 
the brains of V3533-infected µMT mice at days 8, 15, and 70 post-infection and 
assessed expression of IFNγ, TNFα, IL-2, IL-10, and IL-17 by intracellular cytokine 
staining.  We also looked at surface expression of CD69 and CD107a as markers of 
recent activation and degranulation, respectively.  Day 8 was chosen to provide a 
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snapshot of T cell behavior during the peak of antiviral activity, as T cell numbers in 
the CNS were increasing and viral titers were decreasing at this time.  Day 15 
represented a point after which both viral titers and T cell numbers within the CNS 
had decreased substantially and recovery had begun.  Day 70 was chosen to 
represent a point well into the chronic phase of infection. 
 
T cell behavior within the brains of V3533-infected mice was described using two 
complementary approaches.  The first was to non-specifically stimulate brain-
infiltrating T cells with PMA and ionomycin for 6 hours ex vivo prior to flow cytometric 
analysis to determine how these cells were capable of responding (Fig 6A).  Using 
this approach, it appeared that both CD4+ and CD8+ cells were programmed to 
respond similarly to V3533 infection within the brain.  Large numbers of IFNγ and 
TNFα-producing CD4+ and CD8+ cells were detected, while IL-17 and IL-10-
producing cells were much less prevalent, indicating that both CD4+ and CD8+ cell 
populations appeared to be participating in a predominantly Th1-skewed response.    
IL-2 production was minimal, in accordance with previous findings during Sindbis 
infection (26).  The numbers of IFNγ and TNFα-producing CD4+ and CD8+ cells were 
roughly equivalent at day 8, but by day 15 the number of CD8+ cells producing both 
cytokines was approximately two-fold higher compared with CD4+ cells, reflecting an 
overall increase in the ratio of total CD8+ cells to CD4+ cells at this time-point.  At all 
time-points, a higher percentage of CD8+ cells stained positive for surface 
expression of the recent degranulation marker CD107a, compared with CD4+ cells.  
These results suggest that brain-infiltrating CD4+ and CD8+ T cells were similar in 
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their abilities to produce IFNγ and TNFα ex vivo during the acute phase response to 
V3533, and that the degranulation activity of CD8+ T cells was superior to that of 
CD4+ cells.  Both CD4+ and CD8+ T cells retained multiple effector capabilities well 
into the chronic phase of VEEV infection, indicating that the phenomenon of T cell 
exhaustion was not occurring in this system (Table 1).  The caveat with results 
obtained by PMA/ionomycin treatment however, is that they represent only how T 
cells are programmed to respond, not how they are actually behaving in vivo. 
 
A second approach gave a more direct measurement of how T cells were actually 
behaving in vivo.  Rather than treating with PMA and ionomycin following isolation, 
brain-infiltrating T cells were treated only with brefeldin A, with or without monensin, 
prior to flow cytometric analysis (Fig 6B).  No external stimulus was provided.  While 
this treatment probably resulted in artificially low levels of detectable expression due 
to the time lag between sacrifice of the animal and cell fixation, we feel that any 
results observed using this method are the direct result of the stimuli and regulatory 
signals present within the brains of V3533-infected mice.  Brain-infiltrating T cells 
analyzed in the absence of ex vivo stimulus exhibited a dramatically different pattern 
of IFNγ and CD107a expression compared to that observed following 
PMA/ionomycin treatment.  At days 8, 15, and 70 post-infection, significant IFNγ 
expression was detectable only within the CD4+ population.  IFNγ+ CD8+ T cells were 
undetectable at all timepoints.  In addition, a larger percentage of CD4+ cells 
expressing surface CD107a were detected, compared with CD8+ cells during the 
acute phase. Finally, IL-2, IL-17, and IL-10 expressing cells were sparse in both 
  144 
CD4+ and CD8+ T cells.  Together, these results indicate that during the acute phase 
of the response to V3533 infection within the brain, CD4+ T cells produced more 
IFNγ and had higher levels of degranulation activity compared with CD8+ T cells, 
potentially explaining why these cells exhibited more potent anti-VEEV activity. 
 
While the lack of known T cell epitopes prevented us from directly examining VEEV-
specific T cells, we felt that the use of CD69 staining provided a reasonable 
alternative.  CD69 expression on T cells serves as a marker of recent encounter with 
cognate antigen, and should not be expressed on bystander T cells (47).  At each 
time point examined, CD69+ cells constituted roughly 50-80% of all CD4+ and CD8+ 
T cells within the brain (Fig 6C).  This is consistent with the majority of brain-
infiltrating T cells being VEEV-specific during both the acute and chronic phases of 
infection. 
 
Discussion 
While the important protective role of B cells and virus-specific antibodies during 
neuronotropic alphavirus infection has been well established, the role of T cells 
remains relatively ill-defined.  Work with avirulent Sindbis virus has suggested that T 
cells might directly act to limit viral infection within the CNS by non-cytolytic 
mechanisms; however, studies using virulent strains of Sindbis or VEEV were 
contradictory, suggesting instead that T cells might either act to enhance pathology 
or play no significant role whatsoever (5, 28, 44).  Previous studies evaluating the 
immune response to VEEV infection have been hampered by the lack of a model 
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system in which successful control of infection could be reliably observed.  To better 
understand the role of T cells during a successful immune response to acute VEEV 
infection, we utilized a mutant of VEEV, V3533, which is capable of invading the 
CNS from the periphery yet only induces a mild, transient disease in immune-
competent mice.  We feel that this provides a more relevant model of VEEV-induced 
disease in humans, compared with the universal lethality observed in mice infected 
with wild-type VEEV strains, as natural infections of humans very rarely progress to 
overt encephalomyelitis and death (58).  Using V3533 infection of mice as a model 
of successful recovery from VEEV-induced encephalomyelitis, we asked whether T 
cells played a significant role during recovery from VEEV infection, independent from 
any effect on antibody production.   We observed that B cell-deficient µMT mice 
were able to recover from V3533 infection while T cell-depleted µMT mice were not, 
clearly demonstrating that T cells could facilitate clinical recovery from VEEV-
induced encephalomyelitis in the absence of antibody.  
 
We chose to carry out these studies in µMT mice, rather than B-cell depleted 
immune-competent mice, in order to ensure that antibody production was completely 
absent.  Given the highly protective effects that antibodies demonstrated in other 
alphavirus infection models, we were concerned that even a small percentage of 
endogenous B cells that survived a depletion treatment might exert enough of an 
effect to confound the potentially subtle T cell-associated effects in which we were 
interested (32).  The use of µMT mice as a “B cell deficient mouse” is complicated by 
the observation that these mice exhibit various T cell deficiencies relative to wild-
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type mice (2).  We cannot rule out that these defects, which affect both expansion 
and function in CD4+ and CD8+ T cells, might contribute to the viral persistence that 
we observed.  However, the fact that T cells are able to control V3533 infection and 
facilitate recovery in µMT mice despite these strain-specific deficiencies strengthens 
our conclusion that T cells contribute a significant anti-viral effect during V3533 
infection.   
 
Viral infection of CNS neurons presents a unique problem for the immune system in 
that they are absolutely essential for host function, yet are not easily replaced (34).  
As a result, widespread immune-mediated cytolysis of infected cells can present a 
greater threat to host viability than the virus itself (10).  In the case of infection with a 
highly virulent virus, the benefits of cytolytic clearance mechanisms might be worth 
the cost in enhanced pathology; however, it appears that the mammalian immune 
system has also evolved non-cytolytic mechanisms of T cell-mediated clearance.  In 
particular, studies with Sindbis virus, Theiler’s murine encephalomyelitis virus 
(TMEV), and measles virus have all implicated T cell-associated IFNγ production in 
mediating noncytolytic clearance of virus from infected neurons (7, 38, 42).   The 
studies described here clearly demonstrated that, during V3533 infection, T cells 
were able to significantly restrict viral replication within the brain and clear infectious 
virus from the spinal cord, thus facilitating recovery from a severe viral 
encephalomyelitis.  While this reduction in CNS titers was clearly associated with 
more severe disease signs, compared with what was observed in Rag1-/- mice, the 
rapid onset of recovery and the absence of long-lived sequelae within the brain 
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suggest that control of the infection was not achieved simply by destruction of 
infected neurons.  
 
The failure of µMT mice to fully clear infectious virus from the CNS mirrors what has 
been previously observed in µMT mice infected with Sindbis virus (5).  The ability of 
these mice to recover from V3533-induced encephalomyelitis despite the continuing 
presence of infectious virus both within the CNS as well as systemically raises a 
number of questions.  The most obvious is, what are the cellular reservoirs of virus 
that prevent total clearance?  Studies with Sindbis virus have indicated that neuronal 
sub-populations within the CNS are differentially susceptible to IFNγ-mediated 
clearance (8).  Whether these differences are due to intrinsic differences in the IFNγ-
signaling network within these cells or some other mechanism remains to be 
determined.  If there is a stable reservoir of clearance-refractory neurons that are 
responsible for the observed persistence, how are those cells able to survive 
prolonged infection with a cytolytic virus?  Despite the presence of robust anti-
apoptotic programming within mature neurons, virulent strains of VEEV are able to 
induce widespread neuronal death (10, 22, 27).  It may be that V3533 is less 
efficient at overcoming these mechanisms, thus allowing long-term survival of 
infected neurons.  If this is the case, understanding the molecular basis of this 
difference will be of great interest.  Another issue that remains unresolved is the 
extent to which host neurological function is compromised by the ongoing persistent 
infection and accompanying low-level inflammatory response (40).  While µMT mice 
appear to recover fully from V3533-induced clinical disease, it is possible that a 
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more in-depth evaluation of cognitive function in the recovered animals might reveal 
subtle defects.   
 
Given the continuing presence of infectious virus within the CNS of recovered µMT 
mice, it is not surprising that activated T cells were retained within the brain and 
spinal cord.  What was somewhat surprising was that both CD4+ and CD8+ T cells 
retained functionality, as determined by IFNγ expression, as long as 70 days 
following infection.  The loss of T cell function, specifically IFNγ expression, has 
been well documented in other models of persistent viral infection and is thought to 
result from prolonged antigen exposure (6, 36, 51).  In this model of persistent VEEV 
infection however, long-term antigen exposure, as indicated by sustained CD69 
expression, was not sufficient to induce exhaustion.  A recent study that examined T 
cell responses to chronic mouse hepatitis virus infection of the CNS also observed 
long-term maintenance of T cell function despite ongoing antigenic stimulation, 
suggesting that some aspect of the CNS regulatory environment might prevent the 
development of the exhaustion phenotype observed in other systems (61).   
 
Another notable aspect of the T cell response that we observed during the sub-
clinical chronic phase of the infection was a shift in CD8+:CD4+ T cell ratios.  While 
this ratio was roughly 1:1 during the acute phase of the response within the CNS, by 
day 20 post-infection it had risen to about 3:1, and by day 70 had reached nearly 
10:1.  One possible explanation for this finding could be increased susceptibility to 
apoptosis among cells of the CD4+ population.  Studies performed in the context of 
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acute LCMV infection showed that CD4+ memory cells have lower levels of Bcl-2 
expression compared with CD8+ memory cells and that this corresponded with a 
more rapid decline in CD4+ T cells over time (24).  Another possible explanation is 
that MHC class I and MHC class II expression within the CNS might be differentially 
regulated during the development of viral persistence (39).  Since viral antigen 
presentation is likely to be required for maintenance of T cell populations during 
chronic infection, it may be that a reduction in MHC class II-restricted presentation 
could result in the gradually diminishing CD4+ T cell numbers that we observed (50).  
More work is needed to describe the dynamics of antigen presentation within the 
CNS during chronic viral infection.       
 
It has been firmly established that the CNS presents an especially unique 
microenvironment in which extremely tight regulation of host immune responses is 
essential for continued host viability (9, 37).  Numerous mechanisms, including 
restricted expression of MHC class I and class II by neurons, and the constitutive 
production of TGFβ and immune-suppressive gangliosides by glial cells, act to limit 
both the magnitude and duration of inflammatory responses, thereby protecting 
against excessive immune-pathology (15, 25, 30, 37, 48).  The complex regulatory 
environment within the CNS might explain our observation that CD4+ T cells appear 
to be providing the majority of T cell-associated antiviral activity in our system.  
Despite both T cell populations having been clearly primed to produce IFNγ, as 
evidenced by the response to PMA/ionomycin treatment, the absence of detectable 
IFNγ expression by unstimulated brain-infiltrating CD8+ T cells during the acute 
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response to V3533 suggests that CD4+ and CD8+ cells are subject to differential 
regulation within the brain.  This observation could be explained by a failure of 
infected neurons to upregulate MHC class I, preventing antigen encounter, but this is 
unlikely as the vast majority of CD8+ T cells retain a CD69+ phenotype both during 
the acute and chronic phases of the response to V3533, indicating recent encounter 
with cognate antigen.  It seems more likely that some environmental factor is 
specifically limiting IFNγ production by CD8+ cells within the brain.  There is 
precedent for this, as CNS-infiltrating CD4+ T cells responding to Sindbis virus 
infection appear deficient in IL-2 expression, compared with CD4+ T cells in the 
periphery (26).  Other studies have shown that T cells primed by brain-resident 
microglia take on a phenotype that is distinct from T cells primed by other APC 
populations (16).  Clearly, further work is needed to better define the regulatory 
elements within the CNS that dictate T cell function during VEEV infection.   
 
Our observation that, within this highly reductionist model, CD4+ cells played a 
significantly more potent anti-viral role in response to V3533 compared with CD8+ 
cells correlated with substantially higher levels of IFNγ expression and signs of 
recent degranulation.  This differs from results obtained in Sindbis virus-infected 
mice, where CD4+ and CD8+ T cells appeared to have equivalent effects on viral 
titers within the CNS (5).  Based on our CD8 depletion studies in µMT mice, CD4+ T 
cells appear to exert considerable anti-viral effect, independent of any role in helping 
B cell or CD8+ T cell responses.  This effect is most likely mediated primarily by IFNγ 
signaling within infected neurons, similar to what has been described with Sindbis 
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virus, Borna virus, TMEV, and measles virus (7, 23, 38, 42).  However, we cannot 
rule out additional mechanisms.  One possible alternative mechanism could involve 
the release of lytic granules as CD4+ T cells and, to a lesser extent, CD8+ T cell both 
exhibited signs of recent degranulation both during and after the acute phase 
response.  Lytic granule release could act to clear V3533 from infected neurons 
either by cytotoxic mechanisms (i.e. perforin release), as has been described during 
West Nile virus infection, or by non-lethal mechanisms, as has been described 
during HSV-1 infection (31, 52).  A second possible alternative mechanism is that 
CD4+ T cells, possibly through IFNγ expression, might act to enhance 
monocyte/microglia responses to the virus, as has been observed following LCMV 
infection of the CNS (33).  Obviously, these different mechanisms are not mutually 
exclusive.  Given that neurons do not express MHC class II, the mechanism by 
which CD4+ T cells recognize V3533-infected neurons also remains unclear (41).    
 
In summary, our results confirm the established importance of anti-viral antibodies in 
limiting disease following neuronotropic alphavirus infection, but also clearly 
demonstrate that T cells can facilitate recovery from severe viral encephalomyelitis 
in the absence of antibodies.  The recovery that we observed in V3533-infected µMT 
mice was associated with a dramatic reduction in viral titers within the CNS, followed 
by the establishment of a persistent sub-clinical infection.  These results 
demonstrate for the first time that T cells are able to directly control infection by a 
neuronotropic virus that causes encephalomyelitis in humans.  We also showed that, 
in the context of VEEV infection, the majority of T cell-associated antiviral activity 
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resides within the CD4+ population, possibly due to significantly enhanced IFNγ 
expression in these cells compared with CD8+ cells.  Taken together, these studies 
suggest that the promotion of T cell effector function, within both CD4+ and CD8+ 
populations, should be an important consideration when designing and evaluating 
new vaccines against encephalitic alphaviruses.   
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Figure 3.1 (Figure 1) 
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Figure 1:  V3533 induces mild, transient disease followed by clearance in 
C57BL/6. (A) 7-10 week old female C57BL/6 mice were inoculated with 106 pfu of 
V3533 by infection in the left rear footpad. At the indicated days post-infection (Day 
P.I.) serum, spleen, brain, and spinal cord were collected from V3533-infected mice 
and homogenized.  The amount of infectious virus present in serum, spleen, brain, 
and spinal cord was then quantified by plaque assay on BHK-21 cells.  Data is 
presented as the mean +/- standard deviation of results pooled from two 
independent experiments with 3-10 animals per timepoint.  Dotted line represents 
the limit of detection.  (B) 7-10 week old female C57BL/6 mice were inoculated with 
103 pfu of wild-type VEEV (V3000) or 106 pfu of V3533 by infection in the left rear 
footpad.  Mock-infected mice were infected with diluent alone.  Mice were weighed 
daily, with those losing more than 20% of their starting weight being euthanized as 
required by UNC IACUC regulations. *, p<0.05 by Mann-Whitney. 
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Figure 3.2 (Figure 2) 
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Figure 2:  Rag1-/- mice succumb to V3533 infection while µMT mice recover.  7-
10 week old female µMT or Rag1-/- mice were inoculated with 103 pfu of V3533 by 
injection in the left rear footpad.  C57BL/6 mice received 106 pfu of V3533. (A) Mice 
were weighed daily, with those losing more than 35% of their starting weight being 
euthanized as required by UNC IACUC regulations.  (B) Mice were scored for the 
development of encephalomyelitis based on the following scale: 1 – hunched 
posture; 2 – ruffled fur; 3 – ataxia, imbalance; 4 – conjunctivitis; 5 – hind limb 
paresis/paralysis; 6 – moribund.  Each data point represents the mean +/- SEM of 6 
animals per group from a single, representative experiment.
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Figure 3.3 (Figure 3) 
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Figure 3:  Recovery in µMT mice is associated with control of viral replication 
in the brain, clearance in the spinal cord.  7-10 week old female µMT or Rag1-/- 
mice were inoculated with 103 pfu of V3533 by injection in the left rear footpad.  (A) 
At the timepoints indicated serum, spleen, brain, and spinal cord were collected from 
infected µMT mice and homogenized.  The amount of infectious virus present in 
serum, spleen, brain, and spinal cord was then quantified by plaque assay on BHK-
21 cells.  Data points represent individual tissue titers pooled from two independent 
experiments.  (B) Tissue titers from infected µMT mice at day 105 post-infection.  (C) 
Comparison of tissue titers between µMT and Rag1-/- mice.   Data is presented as 
the mean +/- SEM of titer values from 3-4 animals per group.  In all cases, dotted 
line represents the limit of detection. 
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Figure 3.4 (Figure 4) 
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Figure 4:  Reduction of viral titers in the CNS coincides with influx of T cells, 
inflammatory monocytes. 7-10 week old female µMT mice were inoculated with 
103 pfu of V3533 or diluent alone by injection in the left rear footpad.  At various 
timepoints post-infection, mice were perfused with PBS and CNS-infiltrating 
leukocytes were isolated.  Infiltrating cells were stained for various surface markers 
and analyzed by flow cytometry.  (A) Representative dot plots illustrating the gating 
scheme used to define cell populations.  (B) Total numbers of microglia 
(CD11b+/CD45lo), inflammatory monocytes (CD11b+/CD45hi), CD4+ T cells 
(CD3+/CD4+), and CD8+ T cells (CD3+/CD8+) isolated from brain and spinal cord.  
For each timepoint, data is presented as the mean +/- the standard error of 3-4 mice 
and is representative of 2 independent experiments.  (C) Comparison of total cell 
numbers of indicated infiltrating leukocyte populations between mock and V3533-
infected mice 70 days post-infection.  Data is presented as means +/- standard error 
of four animals per group.  *, p<0.05 by Mann-Whitney. 
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Figure 3.5 (Figure 5) 
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Figure 5:  T cells are required for control of infection, recovery in µMT mice. 7-
10 week old female µMT mice were treated with depleting antibodies against CD3, 
CD4, or CD8, or with an isotype control antibody, and then inoculated with 103 pfu of 
V3533 by injection in the left rear footpad.  Depletion treatments were continued for 
25 days post-infection, at which point the experiment was terminated.  (A) 
Representative dot plots of CD3+ splenocytes from each group, taken at day 25 
post-infection.  (B) Effect of T cell depletions on weight loss following V3533 
infection.  Data presented as mean +/- standard error of 4-5 animals per group.  (C) 
Infectious virus from tissues harvested 25 days post-infection, assessed by plaque 
assay on BHK-21 cells.  Each data point represents a single animal, with bars 
indicating the geometric mean.  *, p<0.05 compared to control by Mann Whitney. 
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Figure 3.6 (Figure 6) 
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Figure 6:  CD4+ T cells are the main producers of T cell-associated IFNγ  within 
the brains of V3533-infected µMT mice. 7-10 week old female µMT mice were 
inoculated with 103 pfu of V3533 by injection in the left rear footpad.  At the times 
indicated, mice were perfused with PBS and brain-infiltrating leukocytes were 
isolated.  Harvested cells were then pooled and either (A) cultured in the presence of 
PMA/ionomycin for 6 hours with brefeldin A +/- monensin added for the final 4 hours, 
or (B) cultured in the presence of brefeldin A +/- monensin with no additional 
stimulus for 4 hours.  Following treatment, cells were surface stained for CD3α, 
CD4, and CD8, and then stained for the intracellular presence of multiple cytokines.  
Each bar depicts the number of cells of a given cell type that stained positive for the 
indicated cytokine/surface marker per brain (days 8 & 15) or the percentage of 
pooled cells that stained positive (day 70).  (C) Percentage of T cells positive for 
CD69 surface expression in the absence of ex vivo stimulation.  Data shown was 
generated in a single experiment but is representative of 2-3 independent 
experiments.   
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Table 1.  Percentage of brain-infiltrating T cells expressing indicated cytokines at 
day 70 post-infection 
 
 
 CD4+ PMA/iono. CD8+ PMA/iono. CD4+ Unstim. CD8+ Unstim. 
IFNγ  62.03 77.96 1.92 0.0 
TNFα  40.51 62.84 1.92 3.25 
IL-2 16.91 11.19 1.32 0.0 
IL-17 0.0 0.0 0.0 0.75 
IL-10 18.75 0.93 0.4 0.57 
CD107a 4.81 26.01 0.2 0.0 
 
  
 
 
 
 
CHAPTER 4:   
COMPARISON OF V3000 AND V3533 CELLULAR TROPISM WITHIN THE BRAIN 
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INTRODUCTION 
Once VEEV has invaded the CNS, it predominantly replicates within neurons (2, 4, 
6).  Viral replication within these critical, difficult to replace cells results in cell death, 
usually through the induction of apoptosis (4).  VEEV-induced killing of infected 
neurons is sufficient to induce mortality in mice (1).  Viral infection of neurons 
presents a unique problem for the immune system in that indiscriminate cytolysis of 
infected neurons would most likely present a greater threat to the host than allowing 
the virus to replicate unchecked.  Thus, non-cytolytic mechanisms of controlling viral 
replication and spread are thought to be favored within the CNS (3).  
 
The extreme lethality of VEEV in mice is thought to result from its ability to efficiently 
infect and kill neurons within the CNS.  One possible explanation for the outcome of 
V3533 infection, where viral replication within the CNS does not result in severe 
morbidity or mortality, is that the two mutations that differentiate V3533 from its 
parental virus V3000 alter the in vivo cellular tropism of the virus such that it no 
longer replicates in neurons.  This is quite plausible, given that the two mutations, 
E76K and K116E, occur in the protein responsible for host cell binding, E2 (7).  
Preferentially replication of V3533 in some other, less critical CNS resident cell 
population, such as astrocytes, could explain why the immune-competent mice are 
able to rapidly clear the virus in the absence of severe morbidity.  
 
Therefore, we asked whether the V3533 mutations altered the cellular tropism of 
VEEV within the mouse brain.  To answer the question we used eGFP-expressing 
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VEEV replicon particles (VRP) that were packaged with the glycoproteins from either 
V3000 or V3533 (5).  These VRP should exhibit the exact same cellular tropism as 
full-length virus bearing the same glycoproteins, but should be unable to propagate 
beyond the initially infected cells.  Following intracranial injection, we showed that 
cells infected with either V3000- or V3533-packaged VRP stained positively for the 
neuronal marker NeuN.  Thus, the V3533 mutations do not alter the neuronal 
tropism of VEEV in vivo.     
 
MATERIALS AND METHODS 
VRP production 
VEEV replicon particles (VRP) expressing the enhanced green fluorescence protein 
(eGFP) under the control of the 26S subgenomic reporter were packaged with either 
the V3000 or the V3533 mutant envelope proteins, as described previously (5).  For 
assembly, the appropriate replicon and packaging RNAs were electroporated into 
BHK-21 cells using a Bio-Rad electroporator.  After confirming the absence of 
propagating virus by passage in BHK-21 cells, VRP were concentrated by 
ultracentrifugation and titers were determined by immunohistochemistry on BHK-21 
cells. 
Mouse studies 
C57BL/6 mice were purchased from The Jackson Labs (Bar Harbor, ME) as needed.  
For virus infections, 6-10 week old female mice were anesthetized via intra-
peritoneal (i.p.) injection with a mixture of ketamine (50 mg/Kg body weight) and 
xylazine (15 mg/Kg body weight) and then injected directly in the brain with 106 
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infectious units of VRP in diluent [phosphate buffered saline (PBS) + 1% donor calf 
serum, Ca2+, Mg2+].  Mock-infected mice received diluent alone. 
Immunohistochemistry 
Mice were inoculated intracranially with VRP as described above.  At 24 hours post-
infection, mice were perfused with 4% paraformaldehyde (PFA).  Brains were 
removed and fixed in 4% PFA overnight, and then rehydrated for 24 hours in 30% 
sucrose in PBS.  Following rehydration, brains were frozen in Tissue-Tek OCT 
Compound (Sakura) using a histobath, and sectioned at 10 µm with a cryostat.  
Cryosections were mounted on poly-L-lysine-coated slides and air dried for 30 min.  
Slides were then stained with streptavidin-conjugated anti-NeuN (neuronal nuclei, 
clone A60; Chemicon), anti-GFAP (glial fibrillary acidic protein, clone GA5; 
Chemicon), and anti-CD11b (microglia, clone M1/70; eBioscience).  Following 
incubation with the appropriate biotinylated secondary antibodies (anti-mouse IgG 
and anti-rat IgG; Vector), slides were incubated with a streptavidin-conjugated Alexa 
Fluor 546, washed and dried, and examined with a Nikon FXA microscope.    
 
RESULTS  AND DISCUSSION 
The V3533 mutations do not significantly alter in vivo cellular tropism within 
the CNS 
The mechanism underlying the attenuation of V3533 relative to the V3000 parental 
virus is not yet known.  One potential explanation for how V3533 is able to replicate 
within the CNS without triggering death or even severe morbidity in immune-
competent mice is that the mutations in E2 have altered the in vivo cellular tropism 
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of the virus such that it no longer replicates predominantly in neurons.  If V3533 
instead replicated in non-neuronal cells, cytolytic clearance of the virus could occur 
without the widespread destruction of neurons.  To test whether the in vivo cellular 
tropism within the CNS of V3533 differed from that of V3000, we infected C57BL/6 
mice i.c. with 106 IU of eGFP-expressing VRP, packaged with either the V3000 or 
V3533 glycoproteins.  Animals were sacrificed at 24 hours post-infection, and the 
brains prepared as frozen sections.  Analysis of V3000-eGFP-VRP-infected sections 
by fluorescence microscopy revealed numerous eGFP+ cells within the brain 
parenchyma.  Staining of these sections with NeuN, a neuronal marker, GFAP, an 
astrocyte marker, and CD11b, a microglial marker, revealed that eGFP+ cells 
exclusively costained with the NeuN marker, indicating that the infected cells were 
neurons (Fig. 3.1).  Evaluation of V3533-eGFP-VRP-infected sections revealed a 
similar pattern, with eGFP+ cells exclusively costaining with NeuN.  Thus, V3533 
appears to predominantly target neurons within the CNS, similar to V3000.      
 
The fact that the V3533 mutations did not alter the neuronal tropism of VEEV in vivo 
rules out one potential explanation for the unique attenuation pattern of V3533.  By 
confirming the neuronal tropism of V3533, these results confirm the relevance of 
V3533 infection as a model for VEEV-induced disease and recovery.  Further work 
is needed to determine whether V3533 affects infected neurons differently than 
V3000.  The observation that V3533 is able to establish a persistent infection within 
CNS neurons while V3000 is not, suggests that such differences may exist (1).     
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Figure 4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1:  V3533 mutations do not alter the cellular tropism of VEEV within 
the CNS.  Representative sections from C57BL/6 mice infected intracranially with 
106 infectious units of either V3000-eGFP-VRP or V3533-eGFP-VRP in diluent.  At 
24 hours post-infection, brains were harvested and frozen sections generated.  
Sections were stained for NeuN (neuronal marker), and then evaluated on a Nikon 
FXA microscope.  Images were merged using ImageJ software.   
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CHAPTER 5: 
DISCUSSION AND FUTURE DIRECTIONS 
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All of the studies described here have taken advantage of the unique in vivo 
virulence pattern of the VEEV mutant V3533.  Similar to its lethal parental virus, 
V3000, V3533 replicates and spreads efficiently in the periphery, replicating to high 
titers in multiple lymphoid organs and producing a serum viremia.  This serum 
viremia is sufficient to facilitate viral invasion of the CNS, where V3533 replicates 
predominantly in neurons.  Unlike lethal strains of VEEV, however, V3533 infection 
is halted within the CNS and cleared, resulting in the development of a mild, 
transient febrile illness rather than the uniform lethality that occurs when other 
strains of VEEV make it into the CNS.  In many ways, this better replicates VEEV-
induced disease in humans, where most symptomatic cases present with generic 
“flu-like” symptoms such as fever and headache, and very few immune-competent 
patients progress to overt encephalitis (15).  In addition, as a model of a successful 
recovery from VEEV infection, V3533 infection of C57BL/6 mice allows the 
identification of host factors required for a successful immune response to VEEV 
using knock-out mice, in vivo depletions, and other standard immunological tools.  
Here, we have described studies that used this model to identify previously 
unappreciated protective roles for T cells and the complement system during VEEV 
infection.  A great deal of further work is needed to better understand the 
mechanisms of attenuation for V3533, the actions of complement and T cells during 
VEEV infection, and the requirements for a successful host response to VEEV 
infection. 
 
DETERMINATION OF THE MECHANISMS OF V3533 ATTENUATION 
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The course of infection and disease outcome following V3533 infection of C57BL/6 
mice is unlike that of any other strain of VEEV.  Attenuated VEEV mutants are 
usually unable to spread beyond early sites of replication or invade the CNS (1, 2, 4, 
16).  Those strains of VEEV that do make it into the CNS are typically lethal. V3533 
is unique in its ability to replicate within the CNS without inducing the death of the 
animal.  Determining the mechanisms underlying this attenuation pattern would both 
expand our understanding of alphavirus pathogenesis and potentially provide new 
attenuation strategies for use in live attenuated vaccines. 
 
Efforts to determine where in the infection process V3533 differs from its lethal 
parental virus V3000 would have to start in the periphery.  Previous work has 
suggested that V3533 and V3000 targeted different cells within the draining popliteal 
lymph node (11).  Using a combination of GFP-expressing VRP and double 
promoter viruses, the in vivo cellular tropism of V3000 and V3533 at early sites of 
replication should be more rigorously compared.  Differences in the specific cell 
populations that VEEV infects, and potentially modulates the behavior of, could 
significantly affect the quality of the downstream immune response.  To further 
characterize the effects of the V3533 mutations on early interactions with the host, a 
luminex-based comparison of V3000 and V3533 induced cytokine/chemokine 
production at early sites of infection would also be useful.  An additional approach, 
that would also complement the targeting analysis, would be to compare the gene 
expression profiles of V3000- and V3533-infected cells both within the draining 
lymph node, as well as within cultured dendritic cells, using poly-A binding protein 
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(PABP)-expressing VRP (9).  This would illuminate any differences in the responses 
to these two viruses at the level of the infected cell.   
 
Of greater importance, most likely, would be an analysis of the interactions between 
V3533 and neurons.  The fact that V3533 is able to replicate to high titers within 
CNS neurons without inducing severe morbidity or mortality suggests that there are 
important differences in the ways that V3000 and V3533 interact with these cells.  
The primary function of the E2 glycoprotein is to facilitate cellular attachment, 
however studies with Sindbis virus have suggested an additional role for E2 as a 
determinant of apoptosis induction following infection (6, 10).  Thus, the E2 
mutations present in V3533 could influence replication and spread within CNS, or 
the eventual fate of infected neurons.  Preliminary studies could be carried out in 
primary cortical neuron cultures.  These cells could be used to compare the relative 
neuronal infectivities and replication kinetics of V3533 and V3000.  The use of 
PABP-expressing VRP would be useful for determining whether different patterns of 
neuronal gene expression are induced by the two viruses.  Another key experiment 
would be to compare the kinetics and magnitude of neuronal cell death following 
V3533 and V3000 infection.  One possible explanation for the attenuation of V3533 
is that it is less efficient at killing infected neurons in vivo.  
 
The limited anatomical distribution of inflammation within the brains of V3533-
infected C57BL/6 mice suggests that V3533 is restricted in its ability to disseminate 
within the brain.  Though the exact mechanism of cell-cell spread of VEEV between 
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neurons is not known, there is evidence that the virus follows established neural 
networks in vivo, suggesting a predominant role for trans-synaptic transmission (3).  
In vitro studies using compartmentalized neuronal cultures could shed more light on 
the exact mechanisms of neuron-neuron spread (13).  Infecting mice intra-nasally 
with V3533 and V3000, and then tracking dissemination within the CNS by in situ 
hybridization over short time intervals would indicate whether V3533 was defective 
in spread in vivo.    
 
Finally, the V3533 system remains a virtually untapped resource for dissecting the 
host response to VEEV infection.  Further screening of different knock-out mouse 
strains could identify further unappreciated components of a successful immune 
response to VEEV.      
 
FURTHER EXPLORATION OF VEEV-COMPLEMENT INTERACTIONS 
The infection of C57BL/6 and C3-/- mice with V3533 revealed a role for the 
complement system in limiting the severity of VEEV-induced disease.  More 
specifically, we showed that complement activation within the first 24 hours of 
infection limited the efficiency of neuroinvasion and the extent of downstream viral 
replication and inflammation within the brain.  These results demonstrated that early 
virus-immune interactions can significantly influence the outcome of infection days 
later at distal anatomical sites.  In addition, these studies suggested an important 
role for natural antibody in restricting VEEV-induced pathology.  Finally, in contrast 
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with what has been observed during infection with many other viruses, the induction 
of an anti-VEEV antibody response was not dependent upon complement activation.         
 
Our efforts to understand the complement-dependent mechanisms that are 
important in determining disease outcome following V3533 infection are still 
underway.  As a result, some of the data presented here is still preliminary.  The 
histopathology analysis shown in Figure 2 of the complement chapter grossly 
illustrates that there are differences in the extent of inflammation within the brains of 
wild-type and C3-/- mice, however blinded scoring of a more extensive time-course of 
sections is needed to present a more definitive picture of the effect of complement 
activation on CNS pathology and inflammation.  Efforts to assess the complement 
dependence of the anti-VEEV neutralizing activity of natural antibody still need quite 
a bit of work.  The in vitro anti-VEEV neutralization experiments using normal serum 
need to be repeated, with a tighter dilution curve to generate more robust IC50 
values for comparison.  In addition, the experiment comparing the inflammatory cell 
populations present in the draining lymph nodes of V3533-infected wild-type and C3-
/- mice needs to be repeated with larger group sizes and earlier timepoints.  Finally, 
the comparison of type I IFN levels at early replication sites needs to be repeated for 
earlier timepoints, starting just a few hours after inoculation.  The completion of 
these experiments will allow us to draw more definitive conclusions about the effect 
of complement activation on inflammatory cell recruitment and activation.         
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Our work to date strongly suggests a role for complement activation in facilitating the 
clearance of VEEV from the serum and, as a result, delaying the arrival of VEEV in 
the CNS.  Future work should aim to uncover the molecular interactions between 
VEEV, natural antibody, and complement that govern this effect.  Determining which 
complement activation pathways are being triggered by VEEV infection would be a 
good start.  Preliminary studies suggest that the protective effect of complement in 
vivo is dependent upon C4, but not C1q, suggesting that complement is primarily 
activated through the lectin pathway during VEEV infection (data not shown).  
Further in vitro experiments assessing complement activation and anti-VEEV 
neutralization using serum deficient in each of the three activation pathways could 
better address this question.  To determine which complement components are 
binding and potentially opsonizing VEEV particles, virus could be immuno-
precipitated either following serum incubation in vitro, or directly from the serum of 
viremic mice, and bound complement components could then be detected by 
western blot.  Additional in vivo examination of the effects of complement activation 
on VEEV serum clearance kinetics could either support or contradict our hypothesis 
that serum clearance and neuroinvasion are linked.  Comparing the actual clearance 
rate following intravenous injection of VEEV between wild-type and different 
complement component knock-out mice would be a good first step in this area.    
 
Though the recruitment of inflammatory cells to early sites of V3533 replication 
appears to be complement independent, we cannot yet rule out a role for 
complement-dependent regulation of the effector phenotypes of those cells.  The 
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importance of complement activation in regulating the activation status, but not the 
recruitment, of inflammatory cells during infection with another alphavirus, Ross 
River virus, highlights the importance of addressing this issue (12).  A good starting 
point would be to isolate inflammatory cells from wild-type and C3-/- mice within the 
first 24 hours of infection, and to compare gene expression levels by microarray.  
Candidate genes that are found to be regulated by complement activation could be 
further investigated for potential anti-VEEV activity.   
 
Additional work will be focused on determining the role of C5 cleavage during V3533 
infection.  Some preliminary work using C5-deficient mice has suggested that C5 
cleavage-dependent mechanisms play a role in limiting the development of overt 
encephalomyelitis following V3533 infection (data not shown).  Studies are currently 
underway to confirm that V3533-induced disease is more severe in the absence of 
C5, as well as to assess the effects of C5 on serum clearance and neuro-invasion 
kinetics.   The relevance of these studies to those performed in the C57BL/6 and C3-
/- mice is limited, however, by the fact that the C5-deficient mice are in a different 
genetic background.   
 
Finally, the complement-independent induction of a robust anti-VEEV antibody 
response raises the question of what other virus-induced factors enhance the anti-
VEEV antibody response.  This question could be addressed initially by shutting 
down the various signaling axes known to influence B cell activation through the use 
of knock-out mice and/or adoptive transfer of B cells from knock-out mice.  
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Answering this question could be useful in evaluating future live attenuated vaccine 
candidates.   
 
FURTHER INVESTIGATION OF T CELL RESPONSE DURING VEEV INFECTION 
AND VEEV PERSISTENCE 
Our studies of V3533 infection of µMT mice resulted in several intriguing findings.  
First, T cells can control VEEV replication within the CNS in the absence of antibody, 
facilitating recovery from infection.  Second, CD4+ T cells were better able to control 
VEEV infection within the CNS, relative to CD8+ T cells.  CD8+ T cells did not 
produce detectable amounts IFNγ within the brain during V3533 infection, despite 
being fully capable of producing large amounts in response to ex vivo 
PMA/ionomycin treatment.  Finally, in the absence of antibody, V3533 was able to 
establish a persistent infection in the brain in the absence of apparent morbidity. 
 
The persistent infection that we observed in the µMT mice was surprising, and 
raised a number of intriguing questions.  It would be interesting to determine which 
specific cell population is maintaining the infection.  This could possibly be 
determined through careful in situ hybridization experiments on brain sections taken 
late in infection.  If there is a specific subset of neurons that is completely refractory 
to T cell-mediated clearance, it would interesting to know why.  Additionally, it would 
be worthwhile to fully sequence virus isolates from different anatomical sites at late 
times post-infection.  This might reveal viral sequence elements that influence 
interaction with neuronal cells or viral susceptibility to T cell-induced effector 
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mechanisms.  Finally, while µMT mice persistently infected with V3533 appear 
outwardly normal in their behavior, more in depth examination of their cognitive 
function might reveal subtle defects.  This would allow us to better assess whether 
these mice have truly recovered from infection.    
 
One of the most surprising results of these studies was that CD4+ T cells, in the 
absence of B cells or CD8+ T cells, were able to significantly reduce VEEV titers 
within the CNS.  Neurons are not thought to express MHC class II, so the 
mechanism by which VEEV-specific CD4+ T cells were able to recognize infected 
cells is unclear.  Microglia and astrocytes are the only CNS-resident cells thought to 
express MHC class II, so one possibility is that these cells play some role in 
facilitating contact between VEEV-specific T cells and infected neurons (5).  
Identifying the mechanism by which CD4+ T cells are recognizing VEEV-infected 
neurons would be interesting, but quite difficult, and would probably require 
visualizing the interaction using labeled cells.  This could possibly be performed in 
either ex vivo brain slice cultures, or through live animal imaging (8, 14). 
      
Another interesting observation was the lack of IFNγ production by CD8+ T cells in 
the brains of V3533-infected µMT mice.  This was not due to a generalized defect in 
the CD8+ response in these mice, as CD8+ T cells produced significant amounts of 
another Th1-associated cytokine, TNFα, and were fully capable of producing IFNγ 
ex vivo following PMA/ionomycin treatment.  Instead, it suggests that IFNγ 
production by CD8+ but not CD4+ cells was being specifically suppressed in the 
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brain during V3533 infection.  This finding is similar to the observation that IL-2 
production was specifically repressed in the brains of Sindbis virus infected mice (7).  
To shed light on the mechanism underlying this phenomenon, CD8+ T cells isolated 
from the spleens and brains of V3533-infected µMT mice could be compared to 
determine whether the lack of IFNγ production was brain-specific.  If IFNγ production 
was detectable in the spleen, microarray-based comparisons of spleen- and brain-
infiltrating CD8+ T cells would indicate whether there were corresponding 
differences in gene expression.  The lack of reagents for identifying VEEV-specific T 
cells would complicate this and other potential experiments.  Regardless, pursuing 
this finding could potentially shed some light on the unique immune-regulatory 
environment within the CNS. 
  
Much has been made in the alphavirus field about the role of IFNγ in clearing virus 
from infected CNS neurons.  Our work here did not directly address this issue, but 
did find a correlation between IFNγ production and antiviral activity in T cells during 
V3533 infection.  Future studies should more directly address the relationship 
between IFNγ, VEEV, and neurons in vivo.  Effects seen in IFNγ- or IFNγR- knockout 
mice are complicated by an inability to separate the direct effects of IFNγ on infected 
neurons from other effects in the periphery.  Additionally, teasing apart the antiviral 
and immune-regulatory functions of IFNγ will be difficult.  A good starting point might 
be to use the transfer of IFNγ-knockout T cells prior to V3533 infection to ascertain 
the importance of T cell-derived IFNγ within the CNS.   
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The overall purpose of these studies was to determine whether T cells exerted any 
anti-VEEV effect, independent of antibodies.  While we were able to demonstrate 
that T cells could be quite potent in restricting VEEV replication within the CNS in 
µMT mice, more work is needed to determine the importance of T cell-mediated 
clearance mechanisms in immune-competent animals.  It is quite possible that the 
protective effects of anti-VEEV antibodies are so strong, they render T cell-mediated 
effects superfluous.  Additionally, the potential protective effects of memory T cells 
need to be better studied.  Efforts are currently underway to determine if memory T 
cells generated during V3533 infection can protect naïve mice from lethal VEEV 
challenge.  Answering these questions will help determine how important the 
development of T cell effector function should be as a criterion for evaluating future 
encephalitic alphavirus vaccine candidates.    
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